UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

x	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
	For the fiscal year ended December 31, 2019
¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from [ ] to [ ]
	For the transition period from ________ to _________
Commission file number 001-36604

BIOSCIENCE NEUTRACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada		46-0745348
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 North Michigan Avenue #600, Chicago IL				60611
500 North Michigan Avenue, #600, Chicago IL				60611
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: 773-236-8132

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Name of Each Exchange On Which Registered
Common Stock		$0.0001

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Securities registered pursuant to Section 12(g) of the Act:

N/A ~~(Title of class)~~

~~Indicate~~(Title byof ~~check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 the Securities Act. Yes ¨ No x~~class)

Indicate by check mark if the registrant is ~~not~~a ~~required~~well-known toseasoned ~~file~~issuer, ~~reports~~as ~~pursuant~~defined toin ~~Section~~Rule 13405 ~~or Section 15(d) of~~ the Securities Act. Yes ¨ ☐ No x☒

Indicate by check mark ~~whether~~if the registrant: ~~(1)~~is ~~has~~not ~~filed all reports~~ required to befile ~~filed~~reports bypursuant to Section 13 or Section 15(d) of the ~~Securities Exchange~~ Act ~~of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the last 90 days.~~ Yes x ☐ No ¨☒

Indicate by check mark whether the registrant (1) has ~~submitted~~filed ~~electronically~~all ~~every~~reports ~~Interactive Data File~~ required to be ~~submitted~~filed ~~and~~by ~~posted~~Section ~~pursuant~~13 toor ~~Rule~~15(d) ~~405~~ of ~~Regulation~~the ~~S-K~~Securities ~~(§229.405~~Exchange Act of ~~this~~1934 ~~chapter)~~ during the preceding 12 months (or for such shorter period that the registrant was required to ~~submit~~file such reports), and ~~post~~(2) has been subject to such ~~files)~~filing requirements for the last 90 days. Yes x ☒ No ¨☐

Indicate by check mark ifwhether ~~disclosure~~the ofregistrant ~~delinquent~~has ~~filers~~submitted electronically every Interactive Data File required to be submitted pursuant to ~~Item~~Rule 405 of Regulation S-KT (§~~229~~232.405 of this chapter) isduring ~~not contained herein, and will not be contained, to~~ the ~~best~~preceding of12 ~~registrant’s~~months ~~knowledge, in definitive proxy~~ (or ~~information~~for ~~statements~~such ~~incorporated~~shorter byperiod ~~reference~~that inthe ~~Part~~registrant ~~III~~was ofrequired ~~this Form 10-K or any amendment~~ to ~~this~~submit ~~Form~~such ~~10-K~~files). Yes ☒ No ¨☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨☐ Accelerated filer ¨☐ Non-accelerated filer ¨☒ Smaller reporting company x☒ Emerging Growth Company ¨☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ ☐ No x☒

The aggregate market value of Common Stock held by non-affiliates of the Registrant on June 30, ~~2018~~2019, was $991,~~757~~709,247 based on a $0.4211average ~~average~~ bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter ~~(there was no bid or ask price of our common shares during this quarter)~~.

Indicate the number of shares outstanding of each of the registrant’s classes of common stock as of the latest practicable date.

~~242~~8,042,516 shares of common stock as ~~issued and outstanding~~ of ~~April~~March 512, ~~2019~~2020.

DOCUMENTS INCORPORATED BY REFERENCE

None.

TABLE OF CONTENTS

Item 1.	Business	3
PART I
Item 1B.	Unresolved Staff Comments	6
ITEM 1.	BUSINESS		4
Item 2.	Properties	7
ITEM 1A.	RISK FACTORS		6
Item 3.	Legal Proceedings	7
ITEM 1B.	UNRESOLVED STAFF COMMENTS		6
Item 4.	Mine Safety Disclosures	7
ITEM 2.	PROPERTIES		6
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	7
ITEM 3.	LEGAL PROCEEDINGS		6
Item 6.	Selected Financial Data	8
ITEM 4.	MINE SAFETY DISCLOSURES		6
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	8
PART II
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	11
ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES		7
Item 8.	Financial Statements and Supplementary Data	12
ITEM 6.	SELECTED FINANCIAL DATA		8
Item 9.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure	13
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		8
Item 9A.	Controls and Procedures	13
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK		10
Item 9B.	Other Information	14
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA		10
Item 10.	Directors, Executive Officers and Corporate Governance	15
ITEM 9.	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE		22
Item 11.	Executive Compensation	18
ITEM 9A.	CONTROLS AND PROCEDURES		22
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	19
ITEM 9B.	OTHER INFORMATION		23
Item 13.	Certain Relationships and Related Transactions, and Director Independence	20
PART III
Item 14.	Principal Accounting Fees and Services	21
ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE		24
Item 15.	Exhibits, Financial Statement Schedules	22
ITEM 11.	EXECUTIVE COMPENSATION		27
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS		28
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE		29
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES		29
PART IV
ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES		30
ITEM 16.	FORM 10-K SUMMARY		30
SIGNATURES			31

FORWARD-LOOKING STATEMENTS

This annual report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled “Risk Factors” that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our consolidated financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this annual report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this annual report and unless otherwise indicated, the terms “we”, “us” and “our” mean Bioscience Neutraceuticals, Inc., unless otherwise indicated.

Table of Contents

PART I

~~Item~~ITEM 1. ~~Business~~BUSINESS

~~Forward~~We ~~Looking~~were ~~Statements~~incorporated under the laws of the State of Nevada on June 15, 2010 under the name JobLocationMap Inc. Our principal business objective was developing and marketing an online map application, which has since been discontinued.

~~Although~~On July 10, 2017, we ~~believe~~acquired ~~that~~all of the ~~expectations~~shares ~~reflected~~of inBio ~~the~~Health ~~forward-looking~~Products ~~statements~~Inc. ~~are~~a ~~reasonable~~Nevada corporation, wein ~~cannot~~exchange ~~guarantee~~for ~~future results~~200,000 ~~levels~~shares of ~~activity~~our common stock, ~~performance~~whereby orBio ~~achievements.~~Health ~~Except~~Products asbecame ~~required~~a bywholly ~~applicable~~owned ~~law,~~subsidiary ~~including~~of ~~the~~our ~~securities~~company. ~~laws~~Bio ofHealth Products Inc. had previously acquired the ~~United~~assets ~~States,~~of weEssential doOils, ~~not~~a ~~intend~~sole toproprietorship. ~~update~~Bio ~~any~~Health ofProducts ~~the~~Inc. ~~forward-looking~~was ~~statements~~owned toby ~~conform~~Liang ~~these~~Chen, ~~statements~~the toCEO ~~actual~~of ~~results~~our company.

~~Our~~With ~~consolidated~~the ~~financial~~acquisition ~~statements~~of ~~are~~Bio ~~stated~~Health inProducts ~~United~~(“BHP”) ~~States~~our ~~Dollars~~company ~~(US$)~~changed ~~and~~its ~~are~~focus ~~prepared~~to inthe ~~accordance~~sale ~~with~~of ~~United~~high ~~States~~end ~~Generally~~pure ~~Accepted~~organic ~~Accounting~~oils ~~Principles~~also called “Essential Oils”, which has since been discontinued.

InOn ~~this~~November ~~annual~~14, ~~report~~2018, ~~unless~~our ~~otherwise~~board ~~specified~~of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary, ~~all~~Bioscience ~~dollar~~Neutraceuticals, ~~amounts~~Inc. ~~are~~a ~~expressed~~Nevada incorporation, ~~United~~to ~~States~~effect ~~dollars~~a ~~and~~name ~~all~~change ~~references~~from JobLocationMap, Inc. to ~~“common~~Bioscience ~~shares”~~Neutraceuticals, ~~refer~~Inc. Our company remained the surviving entity. Bioscience Neutraceuticals, Inc. was formed solely for the change of name. Articles of Merger to effect the ~~common~~merger ~~shares~~and inchange ~~our~~of ~~capital~~name ~~stock~~were filed with the Nevada Secretary of State and the change of name was approved by the Financial Industry Regulatory Authority (FINRA) with an effective date of December 12, 2018.

AsOur ~~used~~address inis ~~this~~500 ~~annual~~North ~~report~~Michigan Avenue, ~~the terms “we”~~#600, ~~“us”~~Chicago, ~~“our”~~IL ~~and~~60611. ~~“our~~Our ~~company”~~telephone ~~mean~~number ~~Bioscience~~is ~~Neutraceuticals,~~(773) ~~Inc~~236-8132., ~~and~~We ~~our~~do ~~wholly~~not ~~owned~~have ~~subsidiary, Bio Health Products Inc.,~~ a ~~Nevada~~corporate ~~corporation, unless otherwise indicated~~website.

~~General~~We ~~Overview~~have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

~~We were incorporated under the laws of the State of Nevada on June 15, 2010.~~ Our ~~principal~~Current ~~business objective since incorporation was developing and marketing an online map application.~~ Business

OnWe ~~July~~are ~~10,~~currently ~~2017,~~seeking wenew ~~acquired~~business ~~all~~opportunities ofwith ~~the~~established ~~shares~~business ofentities ~~Bio~~for ~~Health~~merger ~~Products~~with ~~Inc.~~or acquisition of a ~~Nevada~~target ~~corporation~~business. In certain instances, ina ~~exchange~~target ~~for~~business ~~200,000~~may ~~shares~~wish ofto become our ~~common~~subsidiary ~~stock,~~or ~~whereby~~may ~~Bio~~wish ~~Health~~to ~~Products~~contribute ~~became~~assets ato ~~wholly~~us ~~owned~~rather ~~subsidiary~~than ofmerge. ~~our~~We ~~company.~~have ~~Bio~~not ~~Health~~yet ~~Products~~begun ~~Inc.~~negotiations ~~had~~or ~~previous~~entered ~~acquired~~into ~~the~~any ~~assets~~definitive ofagreements ~~Essential~~for ~~Oils~~potential new business opportunities, aand ~~sole~~there ~~proprietorship.~~can ~~Bio~~be ~~Health~~no ~~Products~~assurance ~~Inc.~~that ~~was~~we ~~owned~~will bybe ~~Liang~~able ~~Chen,~~to ~~the~~enter ~~CEO~~into ofany ~~our~~definitive ~~company~~agreements.

~~With~~4 ~~the~~Table ~~acquisition~~ of Bio Health Products (“BHP”) our company is changing its focus to the sale of high end pure organic oils also called “Essential Oils”. We now operate the website www.bestaromaoils.com that was acquired as part of the BHP transaction.Contents

OnAny ~~January~~new 2,acquisition ~~2019~~or ~~majority~~business ofopportunities ~~our~~that ~~shareholders~~we ~~and~~may ~~our~~acquire ~~board~~will ofrequire ~~directors~~additional ~~approved~~financing. aThere ~~reverse~~can ~~stock~~be ~~split~~no onassurance, ahowever, ~~basis~~that ofwe 40will ~~old~~be ~~shares~~able ~~for~~to ~~one~~acquire ~~(1)~~the ~~new~~financing ~~share~~necessary to enable us to pursue our plan of operation. If our ~~issued~~company requires additional financing and ~~outstanding~~we ~~common~~are ~~stock~~unable ~~only~~to acquire such funds, our business may fail.

AsManagement aof ~~result~~our ofcompany ~~the~~believes ~~reverse~~that ~~split,~~there ~~our~~are ~~issued~~benefits ~~and~~to ~~outstanding~~being ~~shares~~a reporting company with a class of ~~common~~securities ~~stock~~quoted ~~decreased~~on ~~from~~the 9OTCQB,~~700,000~~ such as: (i) the ability to ~~242,500~~use ~~shares~~registered ofsecurities ~~common~~to ~~stock.~~acquire ~~The~~assets ~~reverse~~or ~~split~~businesses; ~~will~~(ii) ~~become~~increased ~~effective~~visibility ~~with~~in the ~~OTC~~financial ~~Markets~~community; at(iii) the ~~opening~~facilitation of borrowing from financial institutions; (iv) potentially improved trading onefficiency; ~~February~~(v) 7,potential ~~2019.~~stockholder liquidity; (vi) potentially greater ease in raising capital subsequent to an acquisition; (vii) potential compensation of key employees through stock awards or options; (viii) potentially enhanced corporate image; and (ix) a presence in the United States’ capital market.

~~Our~~We ~~address~~may isseek ~~500~~a ~~North~~business ~~Michigan~~opportunity ~~Avenue~~with entities that have recently commenced operations, ~~#600~~or entities who wish to utilize the public marketplace in order to raise additional capital in order to expand business development activities, ~~Chicago~~to develop a new product or service, ILor ~~60611~~for other corporate purposes. ~~Our~~We ~~telephone~~may ~~number~~acquire isassets ~~(773)~~and ~~236~~establish wholly-~~8132.~~owned Wesubsidiaries doin ~~not~~various ~~have~~businesses aor ~~corporate~~acquire ~~website~~existing businesses as subsidiaries.

WeIn ~~have~~implementing ~~not~~a ~~ever~~structure ~~declared~~for ~~bankruptcy~~a particular business acquisition or opportunity, ~~been~~we inmay ~~receivership~~become a party to a merger, consolidation, reorganization, joint venture, or ~~involved~~licensing inagreement ~~any~~with ~~kind~~another corporation or entity. We may also acquire stock or assets of ~~legal~~an ~~proceeding~~existing business. Upon the consummation of a transaction, it is anticipated that our officers and directors will continue to manage our company.

3As ~~Table~~ of ~~Contents~~the date hereof, we have not entered into any formal written agreements for a business combination or opportunity. When any such agreement is reached, we intend to disclose such an agreement by filing a current report on Form 8-K.

~~Our~~We ~~Current~~anticipate that the selection of a business opportunity in which to participate will be complex and without certainty of success. Business opportunities may be available in many different industries and at various stages of development, all of which will make the task of comparative investigation and analysis of such business opportunities extremely difficult and complex. Business opportunities that we believe are in the best interests of our company may be scarce, or we may be unable to obtain the ones that we want. We can provide no assurance that we will be able to locate compatible business opportunities.

~~Our~~Currently, ~~business~~we isdo ~~focused~~not have a source of revenue. We are not able to fund our cash requirements through our current operations. We have been reliant on ~~the~~loans ~~high~~by ~~end~~affiliated ~~pure~~and ~~organic~~non-affiliated ~~oils~~parties ~~also~~to ~~called~~provide ~~“Essential~~financial ~~Oils~~contributions and services to keep our company operating.” Further, we believe that our company may have difficulties raising capital from other sources until we locate a prospective merger candidate through which we can pursue our plan of operation. If we are unable to secure adequate capital to continue our acquisition efforts, our shareholders may lose some or all of their investment and our business may fail. We currently have no written or oral agreement from our majority shareholder to continue to provide financial contributions.

~~BHP~~5 ~~orders~~Table ~~pure~~of oils wholesale from suppliers and repackages and rebrands them to sell to end consumers. It specializes in a few key product lines currently and has built up its branding by marketing to sell niche lifestyle products that are branded as being very pure and only available in high concentration.Contents

Essential oils can be distilled from leaves, barks, roots and other parts of a plant. They are said therefore to contain the true essence of these plants and can be used then to provide psychological and physical therapeutic benefits. Such oils have been used for thousands of years but it was only in the 1970s to 1980s that these oils started to become a major part of alternative health therapy around the world. Since then people have also started creating cleaners as well as pet remedies from these oils. Essential oils are also widely utilized in cleaning & home products owing to their superior antibacterial and antiseptic properties. Customers are keen on specialized products as various applications require specific characteristics and ingredients.Employees

~~These~~We ~~naturally derived oils~~ have no ~~detrimental~~employees ~~side effect unlike most conventional drugs~~ and ~~medicines,~~our ~~which~~sole isofficer ~~a major driving factor for the essential oil market. Increasing demand for natural personal care products~~ and ~~pleasant~~director ~~aromatic~~who ~~cleaning~~furnishes ~~agents~~their istime ~~expected~~ to ~~foster~~ the ~~industry~~development ~~growth~~of inour ~~these~~company ~~applications.~~at ~~Growing~~no ~~need for aromatic flavors and fragrances in cosmetics, perfumes, as well as spa and relaxation applications is expected to fuel demand in upcoming years~~cost.

~~Most~~ITEM of1A. ~~these~~RISK oils are created by large farm distribution centers which in turn send their products to their industrial partners or to distributors to repackage, brand and also to sometimes dilute down these oils for sale at a retail level.FACTORS

~~Oils~~As ~~can~~a ~~also~~“smaller bereporting ~~used individually or blended to produce additional uses. Single oils for example can be used for arthritis~~company”, ~~muscle~~we ~~pain,~~are ~~colds,~~not ~~diarrhea~~required ~~and~~to ~~blends~~provide ~~can be used for~~ the ~~treatment~~information ofrequired ~~acne,~~by ~~boost~~this ~~immunity and anti-aging~~Item.

~~BHP’s~~ITEM ~~product~~1B. ~~line~~UNRESOLVED ~~consists~~STAFF ~~of:~~COMMENTS

·As ~~Tea Tree Oil is perfect for acne treatment, skin tag removal, dry scalp and dandruff, toe and foot fungus, wart removal, and skin oil remover. · Eucalyptus Oil will act as~~ a ~~nasal~~“smaller ~~decongestant~~reporting to clear sinuses to allow for easier breathing. It will open up air passages so a good comfortable night rest is possible. · Castor Oil is good for hair growth and to grow and strengthen eyelashes and eyebrows. It can also be used as a facial moisturizer and in skin care · Rosehip Oil is for skin and facial carecompany”, ~~helps~~we toare ~~reduces~~not ~~wrinkles~~required and fine lines and has good anti-aging properties · Lemon Oil’s strong citrus scent works well in aromatherapy diffusers and can also be used as a natural household cleaner and disinfectant, and in DIY skin care recipes · Cinnamon Oil is best used for aromatherapy and muscle pain relief. It therefore works well for massages and in anxiety and depression relief · Cedarwood Oil, · Lemongrass Oil can be used for aromatherapy and as a fragrance additive. It also has anti-inflammatory, anti-fungal and bug repellent properties. · Emu Oil will help regenerate skin to provide athe ~~youthful~~information ~~appearance.~~required Itby ~~can~~this ~~be used as a facial toner and it will improve damage from eczema, psoriasis, burn scars, surgical scars, redness, age spots, sun spots, sores, and can also be used to help moisturize dry skin~~Item.

4ITEM ~~Table~~2. ~~of Contents~~PROPERTIES

~~Market~~Our ~~Analysis~~address principal executive office is located at 50 North Michigan Avenue, #600, Chicago IL 60611. Our offices are provided at no cost.

~~Growing~~ITEM ~~consumer preference for natural products has led to the development of innovative applications in personal care and beauty products~~3. ~~Rapid~~LEGAL ~~industrialization and increasing disposable consumer income are the other major factors driving the market growth, especially in developing countries such as China, India, Vietnam, and Thailand.~~PROCEEDINGS

~~The~~From ~~global~~time ~~essential~~to ~~oil~~time, ~~market~~we ~~size~~may ~~exceeded~~become ~~USD~~involved ~~6.0~~in ~~billion~~litigation inrelating ~~2015.~~to ~~Increasing~~claims ~~applications~~arising out of our operations in ~~aromatherapy~~the ~~coupled~~normal ~~with~~course ~~rising~~of ~~demand~~business. ~~for~~We ~~fragrances~~are ~~and~~not ~~flavors~~involved in ~~food~~any &pending ~~beverages~~legal proceeding or litigation and, ~~personal~~to ~~care~~the best of our knowledge, no governmental authority is ~~expected~~contemplating any proceeding to ~~drive~~which ~~market~~we ~~growth~~are ~~over~~a ~~the~~party ~~upcoming~~and ~~years~~which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

~~Improvements~~ITEM ~~in consumer disposable income have driven growth for the Essential Oil Manufacturing industry in the preceding five years to 2016~~4. ~~The~~MINE ~~industry~~SAFETY experienced wavering demand early on in the period, when downstream markets were still amid a sluggish recovery from the decade’s previous lows. Renewed growth in per capita disposable income, however, has gradually boosted purchases of discretionary products such as beauty products and cosmetics, many of which use essential oils. As a result, industry revenue surged by 6.1% in 2014, while demand from downstream markets like cosmetic and beauty product manufacturing and soap and cleaning compound manufacturing each experienced strong recovery in 2015.DISCLOSURES

~~The~~Not ~~global essential oils market is projected to grow at a CAGR of 8~~Applicable.~~6% from 2015 to 2022~~

~~BHP~~6 ~~will~~Table ~~focus~~of ~~on two market segments:~~Contents

·PART Essential Oils: BHP aims to expand the current portfolio of essential oils products and hence capture a greater portion of the current market. This can be done quickly with enough marketing capital since the company currently already has a certain branding and can use that branding to boost revenue from existing customers · Other Beauty Products: BHP is already entrenched within the online ecommerce space for organic products. It will be a natural progression therefore to expand into other similar organic beauty products such as face creams, make up and body care products which would cater strongly to the same clientele, or customers who are looking for products with lower skin sensitivity owing to their organic origins.II

WeMarket face vigorous competition from companies throughout the world, including large multinational consumer products companies that have many essential oil brands under ownership and standalone brands, including those that may target the latest trends or specific distribution channels. Competition in the essential oils industry is based on the introduction of new products, pricing of products, quality of products and packaging, brand awareness, perceived value and quality, innovation, in-store presence and visibility, promotional activities, advertising, editorials, e-commerce and mobile-commerce initiatives and other activities.Information

~~Many~~There ~~multinational~~is consumer companies have greater financial, technical or marketing resources, longer operating histories, greater brand recognition or larger customer bases than we do and may be able to respond more effectively to changing business and economic conditions than we can. Many of these competitors’ products are sold in both a ~~great~~limited ~~number~~public ofmarket ~~retail~~for ~~stores~~our ~~and~~common ~~online as well~~shares. Our ~~competitors~~common ~~may~~shares ~~attempt~~are tolisted ~~gain~~for ~~market~~quotation ~~share~~on bythe ~~offering~~Pink ~~products~~sheets atof ~~prices at or below~~ the ~~prices~~OTC atMarkets ~~which~~under ~~our products are typically offered, including through~~ the ~~use~~trading ofsymbol ~~large percentage discounts and~~ “~~buy one and get one free~~DEVV” ~~offers~~. ~~Competitive~~Trading ~~pricing~~in ~~may~~stocks ~~require~~quoted uson tothe ~~reduce~~Pink ~~our~~Sheets ~~prices,~~is ~~which~~often ~~would~~thin ~~decrease~~and ~~our~~is ~~profitability~~characterized orby ~~result~~wide fluctuations in ~~lost~~trading ~~sales.~~prices ~~Our~~due ~~competitors,~~to many offactors ~~whom~~that ~~have greater resources than we do,~~ may be ~~better~~unrelated ~~able~~ to ~~withstand~~a ~~these~~company’s ~~price~~operations ~~reductions~~or ~~and~~business ~~lost sales~~prospects.

~~Government~~Pink ~~Regulation~~Sheet securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Pink Sheet securities transactions are conducted through a telephone and computer network connecting dealers in stocks. Pink Sheet issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

Additional state and federal requirements may be imposed on consumer products as well as oils, cosmetic ingredients, or the labeling and packaging of products intended for use as oils. For example, several lawmakers are currently focused on giving the FDA additional authority to regulate oils and their ingredients. This increased authority could require the FDA to impose increased testing and manufacturing requirements on cosmetic manufacturers or oils or their ingredients before they may be marketed. We are unable to ascertain what, if any, impact any increased statutory or regulatory requirements may have on our business.Holders

5As ~~Table~~of March 12, 2020, we had 4 shareholders of ~~Contents~~record of our common stock with 8,042,516 shares of common stock outstanding.

In the United States, essential oils are regulated by the U.S. Food and Drug Administration (FDA). To date, there is no universal or regulatory definition of essential oils. However, it is widely understood that essential oils are aromatherapy products extracted from plant sourcesDividends

~~Essential~~We ~~oils~~have ~~are~~not ~~classified~~paid ~~and~~any ~~regulated~~cash bydividends ~~the~~to ~~FDA~~our ~~depending~~shareholders. onThe ~~their~~declaration ~~marketed~~of orany ~~intended~~future ~~use.~~cash ~~The~~dividends ~~FDA~~is ~~may~~at ~~determine~~ the ~~intended~~discretion ~~use~~of ~~through~~our ~~various~~board ~~factors,~~of ~~including~~directors ~~how~~and ~~the~~depends ~~product~~upon isour ~~marketed~~earnings, ~~reviewing~~if ~~label~~any, ~~claims~~our ~~and~~capital ~~wording~~requirements ~~used~~and infinancial ~~advertising.~~position, ~~Essential~~our ~~oils~~general ~~may~~economic ~~also~~conditions, beand ~~evaluated~~other onpertinent ~~a case by case basis~~conditions. ~~Under~~It ~~FDA~~is ~~regulation,~~our ~~essential~~present ~~oils~~intention ~~may~~not ~~fall~~to ~~into~~pay ~~two~~any ~~categories:~~cash ~~cosmetics~~dividends orin ~~drugs.~~the Itforeseeable isfuture, ~~possible~~but ~~for~~rather ~~essential oils~~ to bereinvest ~~considered~~earnings, ~~both~~if aany, ~~cosmetic~~in ~~and~~our abusiness ~~drug~~operations.

IfEquity anCompensation ~~essential~~Plan oil is marketed for the sole purpose of aroma, such as a perfume or body spray, it is considered a cosmetic. Additionally, if an essential oil is only intended for cleansing or beautifying, it can be classified as a cosmetic.Information

IfWe ~~the~~do ~~intended use has been identified as cosmetic in nature, the product is~~ not ~~required~~have toany beequity ~~approved~~compensation ~~by the FDA before it can be sold in the United States~~plans.

~~However,~~7 ~~essential~~Table oils must still comply with the Fair Packaging and Labeling Act (FPLA) and the Federal Food, Drug, And Cosmetic Act (FD&C Act). The FDA holds the right to inspect products, manufacturers, and sellers that they believe may be in violation of ~~these laws.~~Contents

IfRecent anSales ~~essential~~of ~~oil~~Unregistered ~~makes~~Securities; aUse ~~therapeutic claim, it can no longer be regulated as a cosmetic. In the United States, essential oils are often marketed for aromatherapy. By definition, aromatherapy is the use~~ of ~~plant-based~~Proceeds ~~solutions~~from ~~that~~Registered ~~are intended to benefit users mental or physical well-being through different aromas.~~Securities

~~When~~We adid ~~product~~not ~~makes~~sell aany ~~claim~~equity ~~that~~securities ~~affects~~which were not registered under the ~~body,~~Securities ~~prevents~~Act ~~disease~~during orthe ~~treats~~year aended ~~condition~~December 31, it2019 ~~must~~that bewere ~~considered~~not aotherwise ~~drug~~disclosed ~~under~~on ~~FDA~~our ~~regulation.~~quarterly ~~Even~~reports ~~broad~~on ~~claims,~~Form ~~such~~10-Q asor ~~relieving~~our ~~anxiety,~~current ~~can~~reports ~~classify~~on Form 8-K filed during the ~~product~~year asended aDecember ~~drug~~31, 2019.

~~Unlike~~Purchase ~~cosmetics,~~of ~~drugs~~Equity doSecurities ~~need~~by ~~FDA~~the ~~approval~~Issuer ~~before~~and ~~they~~Affiliated ~~can be legally sold to consumers.~~Purchasers

~~Employees~~We did not purchase any of our shares of common stock or other securities during our fourth quarter of our fiscal year ended December 31, 2019.

~~Our~~ITEM ~~company currently has two employees, Mr~~6. ~~Chen~~SELECTED ~~and~~FINANCIAL ~~Eric Steffen, the originator of the Essential Oils, that was acquired by Bio Health Products, and which forms the basis of our company’s ongoing operations.~~DATA

~~WHERE~~As ~~YOU~~a ~~CAN~~“smaller ~~FIND~~reporting ~~MORE~~company”, ~~INFORMATION~~we are not required to provide the information required by this Item.

~~Our~~ITEM ~~Annual~~7. ~~Report~~MANAGEMENT’S onDISCUSSION ~~Form~~AND ~~10-K,~~ANALYSIS ~~Quarterly~~OF ~~Reports~~FINANCIAL onCONDITION ~~Form~~AND ~~10-Q,~~RESULTS ~~Current~~OF Reports on Form 8-K and amendments to reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available from the SEC website at www.sec.gov.OPERATIONS

~~Item~~The 1Afollowing discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. ~~Risk~~The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this Annual Report. Our audited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

AsResults aof ~~“smaller reporting company”, we are not required to provide the information required by this Item.~~Operations

~~Item~~The ~~1B.~~following ~~Unresolved~~summary ~~Staff~~of ~~Comments~~our operations should be read in conjunction with our audited financial statements for the year ended December 31, 2019 and 2018, which are included herein.

As a “smaller reporting company”, we are not required to provide the information required by this Item.

	Year Ended December 31,
	2019			2018			Change			%
Operating Expenses
General and administrative expenses	$	3,514		$	2,055		$	1,459			71	%
Professional fees		34,324			34,245			79			0	%
Stock based compensation		421,912			-			421,912			100	%
Total Operating Expenses		459,750			36,300			423,450			1,167	%
Other expense		166,296			24,955			141,341			566	%
Loss from continued operations		(626,046	)		(61,255	)		(564,791	)		922	%
Loss from discontinued operations		-			(12,283	)		12,283			(100	%)
Net Loss	$	(626,046	)	$	(73,538	)	$	(552,508	)		751	%

6We ~~Table~~recognized ofno ~~Contents~~revenues for the year ended December 31, 2019 and 2018.

~~Item~~Net 2.loss ~~Properties~~increased $552,508 or 751% during the year ended December 31, 2019 due to the increase in operating expenses primarily attributed to the increase in stock based compensation for shares issued to our CEO of $421,912 and increase in other expenses of $141,341 including amortization of debt discount of $137,312

~~Our~~During ~~address~~the ~~principal~~year ~~executive~~ended ~~office~~December is31, ~~located~~2018, atwe 50incurred ~~North~~loss ~~Michigan~~from ~~Avenue,~~discontinued ~~#600~~operations of $12,283 ~~Chicago~~from ILonline ~~60611.~~map ~~Our~~application ~~offices~~business ~~are~~which ~~provided~~was atdisposed noof ~~cost~~during the year ended December 31, 2018.

~~Item~~8 3.Table ~~Legal~~of ~~Proceedings~~Contents

~~From~~Liquidity ~~time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation~~ and, toCapital the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.Resources

~~Item~~Working ~~4. Mine Safety Disclosures~~Capital

Not applicable.

	December 31,			December 31,
	2019			2018			Change			%
Cash and cash equivalents	$	-		$	-		$	-			n/a
Total Assets	$	-		$	6,000		$	(6,000	)		(100	%)
Total Liabilities	$	244,142		$	191,320		$	52,822			28	%
Working Capital	$	(240,185	)	$	(181,363	)	$	(58,822	)		32	%

~~Item~~Cash ~~5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities~~Flows

Our common stock is quoted on the Pink Sheets of the OTC Markets, under the symbol “JBCT”. Our stock was approved for quotation on the OTC Markets on March 3, 2015. However, as of the date of filing this Annual Report, our stock had not traded.

	Year Ended
	December 31,
	2019			2018			Change			%
Cash Flows used in Operating Activities	$	(37,140	)	$	(47,012	)	$	9,872		(21	%)
Cash Flows used in Investing Activities		-			(1,088	)		1,088		(100	%)
Cash Flows provided by Financing Activities		37,140			46,612			(9,472	)	(20	%)
Net Change in Cash	$	-		$	(1,488	)	$	1,488		(100	%)

~~Our~~As ~~transfer~~at ~~agent~~December is31, ~~Action~~2019 ~~Stock~~our ~~Transfer~~company ~~Corporation,~~had ~~2469~~no Ecash and assets. ~~Fort~~As ~~Union~~at ~~Blvd.~~December 31, ~~Suite 214~~2018, ~~Salt~~our ~~Lake~~company ~~City~~had no cash and total assets was $6,000 UTcomprised ~~84121~~of prepaid expense.

As ofat ~~April~~December 531, 2019, weour company had ~~shareholders~~total ~~with~~liabilities ~~242~~of $244,~~516~~142, ~~shares~~of which included convertible notes of ~~common~~$152,190 ~~stock~~and ~~outstanding~~accrued interest of $58,731. As at December 31, 2018, our company had total liabilities of $191,320, of which included due to related parties of $100,172.

~~Dividend~~As ~~Policy~~at December 31, 2019, our company had a working capital deficiency of $240,185 compared with a working capital deficiency of $181,363 as at December 31, 2018. The increase in working capital deficit was primarily due to a decrease in prepaid expense and an increase accrued interest and due to related parties.

WeCash ~~have~~Flow not paid any cash dividends on our common stock and have no present intention of paying any dividends on the shares of our common stock. Our current policy is to retain earnings, if any, for use in our operations and in the development of our business. Our future dividend policy will be determined from ~~time~~Operating ~~to time by our board of directors.~~Activities

~~Equity~~We ~~Compensation~~have ~~Plan~~not ~~Information~~generated positive cash flow from operating activities. For the year ended December 31, 2019, net cash used in operating activities was $37,140 compared to $47,012 used during the year ended December 31, 2018. Cash flows used in operating activities for the year ended December 31, 2019, comprised of a net loss of $626,046, which was reduced by non-cash expenses of $421,912 for stock based compensation and $137,312 for amortization of debt discount, and a net change in working capital of $29,682. Cash flows used in operating activities for the year ended December 31, 2018, comprised of a net loss from continued operations of $61,255 and net loss from discontinued operations of $12,283, which was reduced by non-cash expenses of $4,033 for loss from disposal of assets and a net change in working capital of $22,493.

WeCash doFlow ~~not~~from ~~have~~Investing ~~any equity compensation plans.~~Activities

~~Recent~~During ~~Sales~~the ofyear ~~Unregistered~~ended ~~Securities;~~December ~~Use~~31, of2019, ~~Proceeds~~our ~~from~~company ~~Registered~~did ~~Securities~~not have any investing activities.

WeDuring ~~did not sell any equity securities which were not registered under~~ the ~~Securities Act during the~~ year ended December 31, 2018, ~~that~~net ~~were~~cash ~~not~~used ~~otherwise~~in ~~disclosed~~investing onactivities ~~our~~was ~~quarterly~~$1,088 ~~reports~~from ondisposal ~~Form~~of ~~10-Q~~assets orand ~~our current reports on Form 8-K filed during the year ended December 31, 2018~~liabilities.

~~Purchase~~Cash ofFlow ~~Equity~~from ~~Securities~~Financing ~~by the Issuer and Affiliated Purchasers~~Activities

WeDuring ~~did~~the ~~not~~year ~~purchase~~ended ~~any~~December of31, 2019, our ~~shares~~company received $37,140 from proceeds from issuance of ~~common~~convertible ~~stock~~notes orcompared ~~other~~to ~~securities~~$45,814 ~~during~~from ~~our~~loan ~~fourth~~from ~~quarter~~related parties and $3,957 from notes payable offset by repayment of ~~our~~related ~~fiscal~~party loans of $3,159 during the year ended December 31, ~~2018~~2019.

79 Table of Contents

~~Item~~Liquidity 6.and ~~Selected~~Capital ~~Financial Data~~Resources

AsOur acash ~~“smaller~~balance ~~reporting~~at ~~company”~~December 31, we2019 ~~are~~was ~~not~~$0, ~~required~~with to$240,185 ~~provide~~in outstanding current liabilities, consisting of $1,764 in accounts payable, $58,731 in accrued interest, $152,190 in convertible notes, and $27,500 in notes payable. We estimate total expenditures over the ~~information~~next ~~required~~12 bymonths ~~this~~are ~~Item~~expected to be approximately $75,000.

~~Item~~Contractual ~~7. Management’s Discussion and Analysis of Financial Condition and Results of Operations~~Obligations

~~The~~As ~~following~~a ~~discussion~~“smaller ~~should~~reporting ~~be read in conjunction with our consolidated financial statements~~company”, ~~including~~we the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward looking statements. Factors that could cause or contribute to such differences include, but are not ~~limited~~required to ~~those~~provide ~~discussed~~tabular ~~below~~disclosure ~~and elsewhere in this Annual Report~~obligations. ~~Our audited consolidated financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.~~

~~Results of Operations~~ Off-Balance ~~Years~~Sheet ~~Ended December 31, 2018 and 2017~~Arrangements

~~The~~We ~~following~~have ~~summary~~no ofoff-balance ~~our~~sheet ~~results~~arrangements ofthat ~~operations~~have ~~should~~or beare ~~read~~reasonably inlikely ~~conjunction~~to ~~with~~have ~~our~~a ~~consolidated~~current or future effect on our financial ~~statements~~condition, ~~for~~changes ~~the~~in ~~years~~financial ~~ended~~condition, ~~December~~revenues 31or expenses, ~~2018~~results ~~and~~of ~~2017~~operations, ~~which~~liquidity, ~~are~~capital ~~included~~expenditures ~~herein~~or capital resources that is material to stockholders.

~~Our~~Critical ~~operating~~Accounting ~~results for the year ended December 31, 2018 and 2017, and the changes between those periods for the respective items are summarized as follows:~~Policies

	For the Year Ended
	December 31,
	2018			2017			Change
Revenue	$	-		$	-		$	-
Cost of Goods Sold		-			-			-
Gross Profit		-			-			-
Operating Expenses								-
General and administrative expenses		2,055			1,233			822
Professional fees		34,245			22,095			12,150
Other expense		(24,955	)		(28,143	)		3,188
Loss from discontinued operations		(12,283	)		(98,384	)		86,101
Net Loss	$	(73,538	)	$	(149,855	)	$	76,317

The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

WeRecent ~~did~~Accounting ~~not recognize any revenues during the year ended December 31, 2018 and 2017.~~Pronouncements

~~Net~~Management ~~loss~~has ~~was~~considered ~~$73,538~~all ~~for~~recent ~~year~~accounting ~~ended~~pronouncements ~~December~~issued ~~31,~~since ~~2018 and $149,855 for~~ the ~~year~~last ~~ended~~audit ~~December~~of ~~31,~~our ~~2017~~financial statements. The ~~decrease~~Company’s inmanagement ~~net~~believes ~~loss~~that ~~was~~these ~~primarily~~recent ~~due~~pronouncements towill not have a ~~decrease~~material ineffect ~~loss~~on ~~from~~the ~~discontinued~~Company’s ~~operations~~financial statements.

~~Operating~~ITEM ~~expenses for the year ended December 31, 2018 and December 31, 2017 were $36,300 and $23,328 respectively~~7A. ~~Operating~~QUANTITATIVE ~~expenses~~AND ~~were~~QUALITATIVE ~~primarily~~DISCLOSURES ~~attributed~~ABOUT toMARKET general and administration fees and professional fees. Professional fees for the year ended December 31, 2018, was $34,245 compared to $22,095 for the year ended December 31, 2017. The increase in professional fees during the year ended December 31, 2018, compared to the year ended December 31, 2017, is primarily attributed to an increase in accounting and audit fee. RISK

~~The~~Not ~~decrease in loss from discontinued operations during the year ended December 31, 2018,, compared to the year ended December 31, 2017, is primarily due to an impairment loss of $87,896 in 2017~~Applicable.

ITEM 8. ~~Table~~FINANCIAL ofSTATEMENTS ~~Contents~~AND SUPPLEMENTARY DATA

~~Liquidity~~10 ~~and~~Table ~~Capital~~of Contents

	December 31,			December 31,
	2018			2017
Cash	$	-		$	-
Current Assets	$	6,000		$	4,689
Current Liabilities	$	187,363		$	134,233
Working Capital	$	(181,363	)	$	(129,544	)

Report of Independent Registered Public Accounting Firm

	For the Year Ended
	December 31,
	2018			2017
Cash Flows used in Operating Activities	$	(57,049	)	$	(42,009	)
Cash Flows from Investing Activities		-			(47,972	)
Cash Flows from Financing Activities		46,612			91,469
Net Change in Cash During Period	$	(10,437	)	$	1,488

To the shareholders and the board of directors of Bioscience Neutraceuticals, Inc.

AsOpinion ofon ~~December~~the ~~31,~~Financial 2018, we had a working capital deficit of $181,363 compared to a working capital deficit of $129,544 as of December 31, 2017. The increase in working capital deficit was primarily due to an increase in due to related parties and accounts payable and accrued liabilities. As of December 31, 2018, we had current assets of $6,000 (2017 – $4,689) and current liabilities of $187,363 (2017 – $134,233).Statements

~~Cash~~We ~~Flows~~have ~~from~~audited ~~Operating~~the ~~Activities~~accompanying balance sheets of Bioscience Neutraceuticals, Inc. (the "Company") as of December 31, 2019 and 2018, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

~~For~~Basis ~~the~~for year ended December 31, 2018, net cash flows used in operating activities was $57,049 consisting of a net loss of $73,538 and was offset by loss from disposal of assets of $4,033, and change in operating assets and liabilities of $22,493. For the year ended December 31, 2017, net cash flows used in operating activities was $42,009 consisting of a net loss of $149,855 and was offset by impairment loss of $87,896, amortization of debt discount of $22,878, inventory of $1,675, as well as a gain on debt forgiveness of $1,554, and decrease in accounts payable and accrued liabilities of $3,049Opinion

~~Cash~~These ~~Flows~~financial ~~Used~~statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in ~~Investing~~accordance ~~Activities~~with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

~~For~~We conducted our audit in accordance with the ~~years~~standards ~~ended~~of ~~December~~the ~~31,~~PCAOB. ~~2018~~Those standards require that we plan and ~~2017~~perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, wewhether ~~used~~due $1to error or fraud. The Company is not required to have,~~088~~ ~~and~~nor ~~$47~~were we engaged to perform,~~972~~ an audit of ~~cash~~its ininternal ~~investing~~control ~~activities,~~over ~~respectively~~financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

~~Cash~~Our ~~Flows~~audit ~~from~~included ~~Financing~~performing ~~Activities~~procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

~~For~~Substantial ~~the~~Doubt ~~year~~about ~~ended December 31, 2018, and~~ the ~~December~~Company’s ~~31,~~Ability ~~2017,~~to weContinue ~~generated $46,612 and $94,469 from financing activities, respectively. During the year ended December 31, 2018, cash from financing activities~~ as ~~$45,814~~a ~~from~~Going shareholder loans, $3,957 from notes payable, offset by $3,159 used in repayment of shareholder loans. For the year ended December 31, 2017, cash from financing activities as $57,208 from shareholder loans, $22,878 from convertible notes, $27,500 from notes payable, offset by $8,010 used in repayment of shareholder loans, and $8,107 repayment of loans.Concern

9The ~~Table~~accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of ~~Contents~~this uncertainty.

~~Liquidity~~/s/ ~~and~~BF ~~Capital~~Borgers ~~Resources~~CPA PC

~~Our~~BF ~~cash~~Borgers ~~balance~~CPA at December 31, 2018 was $0, with $187,363 in outstanding current liabilities, consisting of $36,813 in accounts payable, $100,172 due to a related party, $22,878 in convertible notes and $27,500 in notes payable. We estimate total expenditures over the next 12 months are expected to be approximately $75,000.PC

~~Contractual~~We ~~Obligations~~have served as the Company's auditor since 2017.

~~As a “smaller reporting company”~~Lakewood, weCO ~~are not required to provide tabular disclosure obligations.~~

~~Off-Balance~~March ~~Sheet~~30, ~~Arrangements~~2020

We11 ~~have~~Table ~~no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results~~ of ~~operations, liquidity, capital expenditures or capital resources that is material to stockholders.~~Contents

~~Critical~~BIOSCIENCE ~~Accounting~~NEUTRACEUTICALS, ~~Policies~~INC.

~~The~~BALANCE preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on our financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Our financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.SHEETS

Recent Accounting Pronouncements

	December 31,			December 31,
	2019			2018
ASSETS
Current Assets
Prepaid expense	$	-		$	6,000
Total Current Assets		-			6,000

Total Assets	$	-		$	6,000

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	1,764		$	7,066
Accrued interest		58,731			29,747
Due to related parties		-			100,172
Convertible notes		152,190			22,878
Notes payable		27,500			27,500
Total Current Liabilities		240,185			187,363

Long-term note payable		3,957			3,957

Total Liabilities		244,142			191,320

STOCKHOLDERS’ DEFICIT
Preferred Stock, par value $0.0001, 50,000,000 shares authorized, 0 shares issued and outstanding, respectively		-			-
Common Stock, par value $0.0001, 100,000,000 shares authorized, 8,042,516 and 242,516 shares issued and outstanding, respectively		804			24
Additional paid-in capital		699,367			132,923
Accumulated deficit		(944,313	)		(318,267	)
Total Stockholders’ Deficit		(244,142	)		(185,320	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	-		$	6,000

In September 2017, the FASB has issued Accounting Standards Update (ASU) No. 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842): Amendments to SEC Paragraphs Pursuant to the Staff Announcement at the July 20, 2017 EITF Meeting and Rescission of Prior SEC Staff Announcements and Observer Comments.” The ~~amendments~~accompanying innotes ~~ASU~~are ~~No.~~an ~~2017-13~~integral ~~amends~~part ~~the early adoption date option for certain companies related to the adoption~~ of ~~ASU~~these ~~No.~~audited ~~2014-09~~financial ~~and ASU No~~statements. 2016-02. Both of the below entities may still adopt using the public company adoption guidance in the related ASUs, as amended. The effective date is the same as the effective date and transition requirements for the amendments for ASU 2014-09 and ASU 2016-02.

1012 Table of Contents

InBIOSCIENCE ~~May 2014~~NEUTRACEUTICALS, the FASB issued an accounting standards update which modifies the requirements for identifying, allocating, and recognizing revenue related to the achievement of performance conditions under contracts with customersINC. This update also requires additional disclosure related to the nature, amount, timing, and uncertainty of revenue that is recognized under contracts with customers. This guidance is effective for fiscal and interim periods beginning after December 15, 2017 and is required to be applied retrospectively to all revenue arrangements. The adoption of this guidance is not expected to have a significant impact on our company’s consolidated financial statements.

InSTATEMENTS ~~January~~OF 2017, the FASB has issued Accounting Standards Update (ASU) No. 2017-04,” Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” These amendments eliminate Step 2 from the goodwill impairment test. The annual or interim goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. Effective for public business entities that are a SEC filers for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. ASU 2017-04 should be adopted on a prospective basis.OPERATIONS

In January 2017, the FASB issued ASU No. 2017-01,” Business Combinations (Topic 805): Clarifying the Definition of a Business.” This new standard clarifies the definition of a business and provides a screen to determine when an integrated set of assets and activities is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This new standard will be effective for our company on January 1, 2018, however, early adoption is permitted with prospective application to any business development transaction.

	Year Ended
	December 31,
	2019			2018

Operating Expenses
General and administration	$	3,514		$	2,055
Professional		34,324			34,245
Stock based compensation		421,912			-
Total operating expenses		459,750			36,300

Net loss from operations		(459,750	)		(36,300	)

Other expense
Interest expense		(166,296	)		(24,955	)
Total other expense		(166,296	)		(24,955	)

Net loss before taxes		(626,046	)		(61,255	)
Provision for income taxes		-			-
Loss from Continuing Operations		(626,046	)		(61,255	)

Discontinued operations
Loss from discontinued operations		-			(8,250	)
Loss on disposal of assets and liabilities		-			(4,033	)
Loss from Discontinued Operations, Net of Tax Benefits		-			(12,283	)

Net loss	$	(626,046	)	$	(73,538	)

Net Loss Per Common Share – Basic and Diluted	$	(0.10	)	$	(0.30	)

Weighted Average Common Shares Outstanding		6,371,283			242,516

~~Item~~The ~~7A.~~accompanying ~~Quantitative~~notes ~~and~~are ~~Qualitative~~an ~~Disclosures~~integral ~~About~~part ~~Market~~of ~~Risk~~these audited financial statements.

As13 aTable ~~“smaller~~of ~~reporting company”, we are not required to provide the information required by this Item.~~Contents

11BIOSCIENCE ~~Table~~NEUTRACEUTICALS, ~~of Contents~~INC.

~~Item~~STATEMENTS 8.OF ~~Financial~~STOCKHOLDERS’ ~~Statements and Supplementary Data~~EQUITY

~~PART~~FOR ITHE -YEAR ~~FINANCIAL~~ENDED ~~INFORMATION~~DECEMBER 31, 2019 AND 2018

12 Table of Contents

	Preferred Stock				Common stock				Additional Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance, December 31, 2017		-	$	-		242,516	$	24	$	115,161	$	(244,729	)	$	(129,544	)

Debt forgiveness		-		-		-		-		17,762		-			17,762
Net loss for the period		-		-		-		-		-		(73,538	)		(73,538	)

Balance, December 31, 2018		-	$	-		242,516	$	24	$	132,923	$	(318,267	)	$	(185,320	)

Common stock issued for service		-		-		7,000,000		700		421,212		-			421,912
Common stock issued for conversion of debt		-		-		800,000		80		7,920		-			8,000
Beneficial conversion feature		-		-		-		-		137,312		-			137,312
Net loss for the period		-		-		-		-		-		(626,046	)		(626,046	)

Balance, December 31, 2019		-	$	-		8,042,516	$	804	$	699,367	$	(944,313	)	$	(244,142	)

~~Report~~The ofaccompanying ~~Independent~~notes ~~Registered~~are ~~Public~~an ~~Accounting~~integral ~~Firm~~part of these audited financial statements.

To14 ~~the~~Table ~~shareholders and the board~~ of ~~directors of Bioscience Neutraceuticals, Inc.~~Contents

~~Opinion~~ BIOSCIENCE onNEUTRACEUTICALS, ~~the Financial Statements~~INC.

WeSTATEMENTS ~~have~~OF ~~audited~~CASH the accompanying consolidated balance sheets of Bioscience Neutraceuticals, Inc. as of December 31, 2018 and 2017, the related statements of operations, stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.FLOWS

Basis for Opinion

	Year Ended
	December 31,
	2019			2018

Cash Flows from Operating Activities:
Net loss from Continued Operations	$	(626,046	)	$	(61,255	)
Net loss from Discontinued Operations		-			(12,283	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		421,912			-
Amortization of debt discount		137,312			-
Loss from disposal of assets		-			4,033
Changes in operating assets and liabilities:
Inventory		-			(1,715	)
Prepaid expense		6,000			(6,000	)
Accounts payable and accrued liabilities		(5,302	)		5,253
Accrued interest		28,984			24,955
Net Cash Used in Operating Activities		(37,140	)		(47,012	)

Cash Flows from Investing Activities:
Disposal of assets and liabilities		-			(1,088	)
Net Cash Used in Investing Activities		-			(1,088	)

Cash Flows from Financing Activities:
Loan from related parties		-			45,814
Proceeds from issuance of convertible notes		37,140			-
Repayments of related party loans		-			(3,159	)
Proceeds from notes payable		-			3,957
Net Cash Provided by Financing Activities		37,140			46,612

Net Change in Cash and Cash Equivalents		-			(1,488	)
Cash and Cash Equivalents, beginning of period		-			1,488
Cash and Cash Equivalents, end of period	$	-		$	-

Supplemental Disclosure Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Non Cash Investing and Financing Activities
Common stock issued for conversion of debt	$	8,000		$	-
Beneficial conversion feature	$	137,312		$	-
Forgiveness of debt by related party to contributed capital	$	-		$	17,762

~~These~~The ~~financial~~accompanying ~~statements~~notes are ~~the responsibility of the Company's management. Our responsibility is to express~~ an ~~opinion~~integral onpart ~~the~~of ~~Company's~~these audited financial statements ~~based on our audit~~. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We15 ~~conducted~~Table ~~our audit in accordance with the standards~~ of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Contents

~~Our~~BIOSCIENCE ~~audit included performing procedures to assess the risks of material misstatement of the financial statements~~NEUTRACEUTICALS, ~~whether due to error or fraud, and performing procedures that respond to those risks~~INC. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

~~Substantial~~NOTES ~~Doubt~~TO ~~about~~THE ~~the~~FINANCIAL ~~Company’s Ability to Continue as a Going Concern~~STATEMENTS

~~The~~DECEMBER ~~accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements~~31, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.2019

~~/S/~~NOTE BF1 ~~Borgers~~– ~~CPA~~ORGANIZATION PCAND DESCRIPTION OF BUSINESS

BFOrganization, ~~Borgers~~Nature ~~CPA~~of PCBusiness and Trade Name

WeBioscience ~~have~~Neutraceuticals, ~~served~~Inc. as(the Company) was incorporated in the State of Nevada on June 15, 2010 under the name JobLocationMap Inc. The Company's ~~auditor~~is ~~since~~located ~~2017~~at 500 North Michigan Avenue #600, Chicago, Illinois.

~~Lakewood,~~The COCompany’s activities are subject to significant risks and uncertainties including failing to secure additional funding to operationalize the Company’s future operations. The Company is currently evaluating and reviewing the future course of business.

~~April~~Disposal 5,of ~~2019~~business

F-On October 1, ~~Table~~2018, the Company disposed of ~~Contents~~its previous online application business. The change of the business qualified as a discontinued operation of the Company and accordingly, the Company has excluded results of the operations from its Statements of Operations to present this business in discontinued operations.

~~BIOSCIENCE~~Reverse ~~NEUTRACEUTICALS,~~Stock ~~INC.~~Split

~~CONSOLIDATED~~On ~~BALANCE~~January ~~SHEETS~~18, 2019, a majority of our shareholders approved a reverse stock split on a basis of 40 old shares for one (1) new share of our issued and outstanding common stock. The reverse split has been reviewed by the Financial Industry Regulatory Authority and has been approved for filing with an effective date of February 7, 2019. All share and per share information in these financial statements retroactively reflect this stock distribution.

	December 31,			December 31,
	2018			2017
ASSETS
Current Assets
Prepaid expense	$	6,000		$	-
Assets from discontinued operations		-			4,689
Total Current Assets		6,000			4,689
Total Assets	$	6,000		$	4,689
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities		36,813			7,562
Due to related parties		100,172			56,125
Convertible notes		22,878			22,878
Notes payable		27,500			27,500
Liabilities from discontinued operations		-			20,168
Total Current Liabilities		187,363			134,233
Long-term note payable		3,957			-
Total Liabilities		191,320			134,233
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.0001, 50,000,000 shares authorized, 0 shares issued and outstanding, respectively		-			-
Common Stock, par value $0.0001, 100,000,000 shares authorized, 242,516 shares issued and outstanding, respectively		24			24
Additional paid-in capital		132,923			115,161
Accumulated deficit		(318,267	)		(244,729	)
Total Stockholders' Deficit		(185,320	)		(129,544	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	6,000		$	4,689

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The ~~accompanying~~accounting ~~notes~~policies ~~are~~presented anin ~~integral~~these ~~part~~footnotes conform to accounting principles generally accepted in the United States of ~~these~~America ~~audited~~and ~~consolidated~~have been consistently applied in the preparation of the accompanying financial statements. These financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity.

~~F-2 Table of Contents~~Reclassifications

~~BIOSCIENCE~~Certain ~~NEUTRACEUTICALS,~~amounts ~~INC~~in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported net (loss).

~~CONSOLIDATED~~Use ~~STATEMENTS~~of ~~OF OPERATIONS~~Estimates

	For the Year Ended
	December 31,
	2018			2017
Revenues	$	-		$	-
Operating Expenses
General and administration		2,055			1,233
Professional		34,245			22,095
Total operating expenses		36,300			23,328
Net loss from operations		(36,300	)		(23,328	)
Other expense
Interest expense		(24,955	)		(28,143	)
Total other expense		(24,955	)		(28,143	)
Net loss before taxes		(61,255	)		(51,471	)
Provision for income taxes		-			-
Loss from Continuing Operations		(61,255	)		(51,471	)
Discontinued operations
Loss from discontinued operations		(8,250	)		(98,384	)
Loss on disposal of assets and liabilities		(4,033	)		-
Loss from Discontinued Operations, Net of Tax Benefits		(12,283	)		(98,384	)
Net loss	$	(73,538	)	$	(149,855	)
Net Loss Per Common Share – Basic and Diluted	$	(0.30	)	$	(0.62	)
Weighted Average Common Shares Outstanding		242,516			239,897

The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on Bioscience Neutraceuticals, Inc.’s financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Bioscience Neutraceuticals, Inc.’s financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

~~The~~Cash ~~accompanying~~and ~~notes~~Cash ~~are an integral part of these audited consolidated financial statements.~~Equivalents

FFor purposes of the statement of cash flows, the Company considers all short-3term ~~Table~~debt securities purchased with maturity of ~~Contents~~three months or less to be cash equivalents.

~~BIOSCIENCE~~16 ~~NEUTRACEUTICALS,~~Table ~~INC.~~of Contents

~~CONSOLIDATED~~Revenue ~~STATEMENTS OF STOCKHOLDERS’ EQUITY~~Recognition

~~For~~Revenues are recognized when control of the ~~year~~promised ~~ended~~goods ~~December~~or 31services are transferred to a customer, ~~2018~~in ~~and~~an ~~2017~~amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

									Additional
	Preferred Stock				Common stock				Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance, December 31, 2016		-	$	-		237,516	$	24	$	77,476	$	(94,874	)	$	(17,374	)
Accounts payable and accrued liabilities settled by related parties		-		-		-		-		14,807		-			14,807
Acquisition of Subsidiary		-		-		5,000		-		-		-			-
Beneficial conversion feature		-		-		-		-		22,878		-			22,878
Net loss for the period		-		-		-		-		-		(149,855	)		(149,855	)
Balance, December 31, 2017		-	$	-		242,516	$	24	$	115,161	$	(244,729	)	$	(129,544	)
Debt forgiveness		-		-		-		-		17,762		-			17,762
Net loss for the period		-		-		-		-		-		(73,538	)		(73,538	)
Balance, December 31, 2018		-	$	-		242,516	$	24	$	132,923	$	(318,267	)	$	(185,320	)

	•	identify the contract with a customer;
	•	identify the performance obligations in the contract;
	•	determine the transaction price;
	•	allocate the transaction price to performance obligations in the contract; and
	•	recognize revenue as the performance obligation is satisfied.

~~The~~Under ~~accompanying~~these ~~notes~~criteria, this generally means that the Company recognizes revenue when its products are andelivered ~~integral~~to ~~part~~customers ofin ~~these~~accordance ~~audited~~with ~~consolidated~~the ~~financial~~sales ~~statements~~terms.

~~F-4~~Cost ~~Table~~ of ~~Contents~~Goods Sold

~~BIOSCIENCE~~Cost ~~NEUTRACEUTICALS,~~of ~~INC~~goods sold includes the following expenses; inventory and various expenses related to sell the products through third party services.

~~CONSOLIDATED~~Fair ~~STATEMENTS~~Value OFof ~~CASH~~Financial ~~FLOWS~~Instruments

	For the Year Ended
	December 31,
	2018			2017
Cash Flows from Operating Activities:
Net loss	$	(73,538	)	$	(149,855	)
Adjustments to reconcile net loss to net cash used in operating activities:
Impairment loss		-			87,896
Amortization of debt discount		-			22,878
Debt forgiveness		-			(1,554	)
Loss from disposal of assets		4,033			-
Changes in operating assets and liabilities:
Inventory		(1,715	)		1,675
Prepaid expense		(6,000	)		-
Accounts payable and accrued liabilities		30,208			(3,049	)
Net Cash Used in Operating Activities		(47,012	)		(42,009	)
Cash Flows from Investing Activities:
Acquisition of subsidiary		-			(47,972	)
Disposal of assets and liabilities		(1,088	)		-
Net Cash Used in Investing Activities		(1,088	)		(47,972	)
Cash Flows from Financing Activities:
Loan from related parties		45,814			57,208
Repayments of related party loans		(3,159	)		(8,010	)
Repayments of loans		-			(8,107	)
Proceeds from notes payable		-			22,878
Proceeds from notes payable		3,957			27,500
Net Cash Provided by Financing Activities		46,612			91,469
Net Change in Cash and Cash Equivalents		(1,488	)		1,488
Cash and Cash Equivalents, beginning of period		1,488			-
Cash and Cash Equivalents, end of period	$	-		$	1,488
Supplemental Disclosure Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-Cash Disclosure:
Forgiveness of debt by related party to contributed capital	$	17,762		$	8,273
Accounts payable balances settled by previous owner	$	-		$	6,534
Beneficial conversion feature	$	-		$	22,878

The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as risks inherent in valuation techniques, transfer restrictions and credit risk. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

~~The~~Level ~~accompanying~~1 ~~notes~~– ~~are~~Quoted anprices ~~integral~~in ~~part~~active ofmarkets ~~these~~for ~~audited~~identical ~~consolidated~~assets ~~financial~~or ~~statements~~liabilities.

~~F-5~~Level ~~Table~~2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of ~~Contents~~the assets or liabilities.

~~BIOSCIENCE~~Level ~~NEUTRACEUTICALS,~~3 ~~INC~~– Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

~~NOTES~~In TOaccordance ~~THE~~with ~~CONSOLIDATED~~the ~~FINANCIAL~~fair ~~STATEMENTS~~value accounting requirements, companies may choose to measure eligible financial instruments and certain other items at fair value. The Company has not elected the fair value option for any eligible financial instruments.

As of December 31, 2019 and 2018, the carrying value of cash and cash equivalent, accounts payable and loans that are required to be measured at fair value, approximated fair value due to the short-term nature and maturity of these instruments.

~~NOTE~~17 1Table –of ~~ORGANIZATION AND DESCRIPTION OF BUSINESS~~Contents

~~Organization,~~Beneficial ~~Nature~~Conversion ~~of Business and Trade Name~~Feature

~~Bioscience~~For ~~Neutraceuticals,~~conventional ~~Inc.~~convertible ~~(the~~debt ~~Company)~~where ~~was incorporated in~~ the ~~State~~rate of ~~Nevada~~conversion onis ~~June~~below 15market value, ~~2010 under~~ the ~~name~~Corporation ~~JobLocationMap~~records ~~Inc.~~a ~~Bioscience~~Beneficial ~~Neutraceuticals,~~Conversion ~~Inc.’s~~Feature ~~principal~~(the ~~business~~“BCF”) ~~objective is developing~~ and ~~marketing~~related andebt ~~online map application~~discount. ~~The Company is located at 500 North Michigan Avenue #600, Chicago, Illinois.~~

~~The~~When the Company’s ~~activities~~records ~~are~~a ~~subject~~BCF, tothe ~~significant~~intrinsic ~~risks~~value ~~and~~of ~~uncertainties~~the ~~including~~BCF ~~failing~~is torecorded ~~secure~~as ~~additional~~a ~~funding~~debt todiscount ~~operationalize~~against the ~~Company’s~~face ~~future~~amount ~~operations.~~of ~~The~~the ~~Company~~respective isdebt ~~currently~~instrument ~~evaluating~~(offset to additional paid-in capital) and ~~reviewing~~amortized ~~the~~to ~~future~~interest ~~course~~expense over the life of ~~business~~the debt.

~~Recent~~Basic ~~Developments~~and Diluted Net Loss Per Share

OnNet ~~July~~loss ~~10,~~per ~~2017~~share is calculated in accordance with Codification topic 260, “Earnings Per Share” for the ~~Company~~periods ~~acquired~~presented. ~~all~~Basic ofnet loss per share is computed using the ~~shares~~weighted average number of ~~Bio~~common ~~Health~~shares ~~Products~~outstanding. ~~Inc~~Diluted loss per share has not been presented because there are no dilutive items. aDiluted ~~Nevada~~net ~~corporation~~loss per share is based on the assumption that all dilutive stock options, inwarrants, ~~exchange~~and ~~for~~convertible 5debt are converted or exercised by applying the treasury stock method. Under this method,~~000~~ ~~shares~~options and warrants are assumed exercised at the beginning of the ~~Company’s~~period ~~common~~(or ~~stock~~at the time of issuance, ~~whereby~~if ~~Bio~~later), ~~Health~~and ~~Products~~as ~~Inc.~~if ~~became~~funds aobtained ~~wholly~~thereby ~~owned~~were ~~subsidiary~~used ofto purchase common stock at the ~~Company.~~average ~~Bio~~market ~~Health~~price ~~Products~~during ~~Inc~~the period. ~~had~~Options, ~~previously~~warrants ~~acquired~~and/or ~~the~~convertible ~~assets~~debt will have a dilutive effect, during periods of ~~Essential~~net ~~Oils~~profit, aonly ~~sole~~when ~~proprietorship.~~the ~~Bio~~average ~~Health~~market ~~Products~~price ~~Inc.~~of ~~was~~the ~~owned~~common bystock ~~Liang~~during ~~Chen,~~the period exceeds the ~~CEO~~exercise or conversion price of the items. The Company has not issued any options or warrants or similar securities since inception.

AsFor ~~these transactions are between entities under common control,~~ the ~~Company~~years ~~has~~ended ~~reported~~December ~~the~~31 ~~results of operations for the period in a manner similar to a pooling of interests~~ and ~~has~~2018, ~~consolidated~~respectively, ~~financial results since~~ the ~~initial~~following ~~date~~convertible innotes ~~which the above companies~~ were ~~under~~excluded ~~common~~from ~~control.~~the ~~Assets~~computation ~~and liabilities were combined on their carrying values and no recognition~~ of ~~goodwill~~diluted ~~was~~net ~~made.~~loss ~~The Company has presented earnings~~ per ~~share based on the new parent company~~ shares ~~issued~~as to the ~~former~~result ~~shareholders~~ of the ~~Company.~~computation was anti-dilutive:

Merger with subsidiary and name change

	December 31,		December 31,
	2019		2018
	(Shares)		(Shares)
Convertible notes payable		137,311,970		-

OnIncome November 14, 2018, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary, Bioscience Neutraceuticals, Inc. a Nevada corporation, to effect a name change from JobLocationMap, Inc. to Bioscience Neutraceuticals, Inc. Our company will remain the surviving entity.Taxes

~~Articles~~The ofCompany ~~Merger~~recognizes tothe ~~effect~~tax ~~the~~effects ~~merger~~of ~~and~~transactions ~~change~~in ofthe ~~name~~year ~~were~~in ~~filed~~which ~~with~~such ~~the~~transactions ~~Nevada~~enter ~~Secretary~~into ofthe ~~State~~determination ~~with~~of annet ~~effective~~income, ~~date~~regardless of ~~December~~when ~~12,~~reported ~~2018~~for tax purposes.

~~Disposal~~Recent ofAccounting ~~business~~Pronouncements

OnManagement ~~October~~has 1,considered ~~2018,~~all ~~the~~recent ~~Company~~accounting ~~disposed~~pronouncements ofissued ~~online~~since ~~application business. The change of~~ the ~~business~~last ~~qualified~~audit ~~as a discontinued operation~~ of ~~the~~our ~~Company~~financial ~~and~~statements. ~~accordingly,~~The ~~the~~ Company’s ~~has~~management ~~excluded~~believes ~~results~~that ofthese ~~the~~recent ~~operations~~pronouncements ~~from~~will ~~its~~not ~~Consolidated~~have ~~Statements~~a ofmaterial ~~Operations~~effect toon ~~present~~the ~~this~~Company’s ~~business~~financial ~~in discontinued operations~~statements. ~~Refer to Note 9 for further details.~~

~~Reverse~~NOTE ~~Stock~~3 ~~Split~~– GOING CONCERN

OnThe ~~January~~Company’s ~~18,~~financial ~~2019,~~statements aare ~~majority~~prepared ofusing ~~our~~accounting ~~shareholders~~principles ~~approved~~generally aaccepted ~~reverse~~in ~~stock~~the ~~split~~United onStates aof ~~basis~~America ofapplicable 40to ~~old~~a ~~shares~~going ~~for~~concern, ~~one~~which ~~(1)~~contemplates ~~new~~the ~~share~~realization of ~~our~~assets ~~issued~~ and ~~outstanding~~liquidation ~~common~~of ~~stock.~~liabilities ~~The~~in ~~reverse~~the ~~split~~normal ~~has~~course ~~been~~of ~~reviewed~~business. byHowever, the ~~Financial~~Company ~~Industry~~does ~~Regulatory~~not ~~Authority~~have ~~and has been approved for filing with~~ an ~~effective~~established ~~date~~source of ~~February~~revenues 7,sufficient ~~2019.~~to ~~All~~cover ~~share~~its ~~and~~operating ~~per~~costs ~~share~~and ~~information~~to inallow ~~these~~it ~~financial~~to ~~statements~~continue ~~retroactively~~as ~~reflect~~a ~~this~~going ~~stock distribution~~concern.

~~F-6~~Under ~~Table~~the going concern assumption, an entity is ordinarily viewed as continuing in business for the foreseeable future with neither the intention nor the necessity of ~~Contents~~liquidation, ceasing trading, or seeking protection from creditors pursuant to laws or regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.

~~NOTE~~During 2the –next ~~SUMMARY~~year, OFthe ~~SIGNIFICANT~~Company’s ~~ACCOUNTING~~foreseeable ~~POLICIES~~cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with research and development. The Company may experience a cash shortfall and be required to raise additional capital.

AHistorically, ~~summary~~it ofhas ~~significant~~mostly ~~accounting~~relied ~~policies~~upon ofinternally ~~the~~generated ~~Company~~funds isand ~~presented~~funds tofrom ~~assist~~the insale ~~understanding~~of ~~the~~shares ~~Company’s~~of ~~consolidated~~stock ~~financial~~to ~~statements.~~finance ~~The~~its ~~accounting~~operations ~~policies~~and ~~presented~~growth. inManagement ~~these~~may ~~footnotes~~raise ~~conform~~additional tocapital ~~accounting~~through ~~principles~~future ~~generally~~public ~~accepted~~or inprivate ~~the~~offerings ~~United~~of ~~States~~the ofCompany’s ~~America~~stock ~~and~~or ~~have~~through ~~been~~loans ~~consistently~~from ~~applied~~private ininvestors, ~~the~~although ~~preparation~~there ofcan ~~the~~be ~~accompanying~~no ~~financial~~assurance ~~statements.~~that ~~These~~it ~~financial~~will ~~statements~~be ~~and~~able ~~notes~~to ~~are~~obtain ~~representations~~such offinancing. ~~the~~The Company’s ~~management~~failure ~~who~~to ~~are~~do ~~responsible~~so ~~for~~could ~~their~~have ~~integrity~~a material and ~~objectivity~~adverse effect upon it and its shareholders.

~~Principles~~In the past year, the Company funded operations by using cash proceeds received through the issuance of ~~Consolidation~~common stock and loan from related party. For the coming year, the Company plans to continue to fund the Company through debt and securities sales and issuances until the company generates enough revenues through the operations as stated above.

~~The~~NOTE ~~consolidated~~4 ~~financial~~– ~~statements~~NOTE ~~include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated.~~PAYABLE

~~Use~~On June 9, 2017, the Company issued note payable of ~~Estimates~~$7,500 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand.

~~The~~On ~~preparation~~August of14, ~~financial~~2017, ~~statements~~the inCompany ~~accounting~~issued ~~principles~~note ~~generally~~payable ~~accepted in the United States~~ of ~~America~~$20,000 ~~requires management~~ to ~~make~~a ~~estimates~~third and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periodparty. AThe ~~change~~note inis ~~managements’ estimates or assumptions could have~~ a ~~material~~40 ~~impact~~% oninterest ~~Bioscience~~bearing ~~Neutraceuticals,~~promissory ~~Inc.’s~~note financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Bioscience Neutraceuticals, Inc.’s financial statements reflect all adjustments that ~~management~~is ~~believes~~payable ~~are~~on ~~necessary for the fair presentation of their financial condition and results of operations for the periods presented~~demand.

~~Cash~~On ~~and~~March ~~Cash~~31, ~~Equivalents~~2018, the Company issued note payable of $3,957 to a third party. The note is a 57% interest bearing promissory note that is payable on March 31, 2023.

~~For~~As ~~purposes~~ of ~~the~~December ~~statement~~31, of2019 ~~cash~~and ~~flows~~December 31, 2018, the Company ~~considers~~owed ~~all~~notes ~~short~~payable of $27,500 and $27,500, long-term ~~debt~~note ~~securities~~payable ~~purchased~~of ~~with~~$3,957 ~~maturity~~and $3,957 and accrued interest of ~~three~~$30,712 ~~months~~and or$17,457, ~~less~~respectively. toDuring bethe ~~cash~~year ~~equivalents~~ended December 31, 2019 and 2018, the Company recognized interest expense of $13,257 and $12,699, respectively.

~~Inventory~~18 Table of Contents

~~The~~NOTE ~~Company’s~~5 ~~inventory~~– ~~consists~~CONVERTIBLE ofNOTE oil products. All inventory is finished goods. Inventories are stated at the lower of cost or market value. Inventory is stored off-site and held by a third party. The Company utilizes last-in first-out for inventory items held. Items determined to be obsolete are reserved for. The Company provides for the possible inability to sell its inventories by providing an excess inventory reserve. As at December 31, 2018, the Company determined that no reserve was required.PAYABLE

~~Goodwill~~On December 31, 2017, the Company issued a convertible note of $4,875 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $4,875 and amortized $4,875 for the year ended December 31, 2017. During the year ended December 31, 2019, the convertible note of $4,000 was converted into 400,000 shares of common stock.

WeOn ~~account~~December ~~for~~31, ~~goodwill~~2017, inthe ~~accordance~~Company ~~with~~issued ~~ASC~~a ~~350~~convertible ~~”Intangibles-Goodwill~~note ~~and~~of ~~Other”~~$6,803 ~~(“ASC 350”). ASC 350 requires that goodwill~~ with ~~indefinite~~a ~~lives~~conversion beprice ~~tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value~~ of an$0.01. ~~asset~~The ~~has~~convertible ~~decreased~~note ~~below~~is ~~its carrying value. In addition~~unsecured, ~~ASC~~bears ~~350~~interest ~~requires that goodwill be tested for impairment~~ at ~~the~~57% ~~reporting~~per ~~unit~~annum, ~~level~~has ~~(operating~~no ~~segment~~maturity ordate ~~one~~and ~~level~~due ~~below an operating segment)~~ on andemand. ~~annual~~The ~~basis~~Company ~~and~~recorded ~~between~~a ~~annual~~discount ~~tests~~on ~~when circumstances indicate that~~ the ~~recoverability~~convertible ofnote ~~the~~due ~~carrying~~to ~~amount~~a ofbeneficial ~~goodwill~~conversion ~~may~~feature ~~be in doubt. Application~~ of ~~the goodwill impairment test requires judgment~~$6,803 ~~including the identification of reporting units; assigning assets~~ and ~~liabilities~~amortized ~~to reporting units~~$6,803 ~~assigning~~for ~~goodwill to reporting units, and determining~~ the ~~fair~~year ~~value.~~ended ~~Significant~~December ~~judgments required to estimate the fair value of reporting units include estimating future cash flows~~31, ~~determining appropriate discount rates and other assumptions~~2017. ~~Changes~~During ~~in these estimates and assumptions or~~ the ~~occurrence~~year ofended ~~one~~December or31, ~~more~~2019, ~~confirming events in future periods could cause~~ the ~~actual~~convertible ~~results~~note orof ~~outcomes~~$4,000 towas ~~materially~~converted ~~differ~~into ~~from~~400,000 ~~such~~shares ~~estimates and could also affect the determination~~ of ~~fair~~common ~~value and/or goodwill impairment at future reporting dates~~stock.

~~During~~On ~~the year ended~~ December 31, 2017, wethe ~~determined~~Company ~~that~~issued ~~the~~a ~~carrying~~convertible ~~value~~note of ~~goodwill exceeded its fair value at the measurement date~~$11,200 ~~requiring~~with ~~step~~a ~~two~~conversion inprice ~~the~~of ~~impairment test process~~$0.005. The ~~fair~~convertible ~~value~~note ofis ~~the~~unsecured, ~~goodwill~~bears ~~was~~interest ~~determined~~at ~~primarily~~50% ~~using~~per anannum, ~~income~~has ~~approach~~no ~~based~~maturity ondate ~~the~~and ~~present~~due ~~value~~on ~~of discounted cash flows~~demand. WeThe ~~determined~~Company ~~the~~recorded ~~implied~~a ~~fair~~discount ~~value~~on ~~of goodwill was substantially below~~ the ~~carrying~~convertible ~~value~~note ofdue ~~the~~to ~~reporting unit’s goodwill. Accordingly, we recognized~~ a ~~goodwill~~beneficial ~~impairment~~conversion ~~loss~~feature of $8711,~~896,~~200 ~~which~~and ~~resulted~~amortized in$11,200 ~~goodwill~~for ofthe $0year asended of December 31, 2017.

FOn October 1, 2019, the Company issued a convertible note to an un-7affiliated ~~Table~~party of ~~Contents~~$137,312 to replace the full amount of related party advances that had been provided to the Company through December 31, 2019. The convertible notes are due on demand, bear interest at 20% per annum and are convertible at $0.001 per share for the Company common stock. The discount on convertible notes from beneficial conversion feature of $137,312 was fully amortized during the year ended December 31, 2019. During the year ended December 31, 2019, the Company incurred note interest expense of $7,018.

~~Revenue~~As ~~Recognition~~of December 31, 2019 and 2018, the Company owed convertible notes payable of $152,190 and $22,878 and accrued interest of $28,017 and $12,290, respectively. During the year ended December 31, 2019 and 2018, the Company recognized interest expense of $15,727 and $12,256, respectively.

~~Revenues~~NOTE ~~are~~6 ~~recognized~~– when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:EQUITY

·The ~~identify~~Company ~~the~~has ~~contract~~authorized ~~with~~100,000,000 ashares ~~customer;~~of ·common ~~identify~~stock ~~the~~with ~~performance~~a ~~obligations~~par invalue ~~the~~of ~~contract;~~$0.0001 ·and ~~determine~~50,000,000 ~~the~~shares ~~transaction~~of ~~price;~~preferred ·stock ~~allocate~~with ~~the~~a ~~transaction~~par ~~price~~value toof ~~performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied~~$0.0001.

~~Under~~Preferred ~~these criteria, this generally means that the Company recognizes revenue when its products are delivered to customers in accordance with the sales terms.~~stock

~~Cost~~As of ~~Goods~~December ~~Sold~~31, 2019 and December 31, 2018, there was no shares issued and outstanding.

~~Cost~~Common ~~of goods sold includes the following expenses; inventory and various expenses related to sell the products through third party services.~~stock

~~Fair~~During ~~Value~~the year ended December 31, 2019, the Company issued 7,800,000 shares of ~~Financial~~common ~~Instruments~~stock as follows;

	•	7,000,000 shares to our CEO for compensation

	•	800,000 shares for conversion of debts of $8,000

~~Level~~8,042,516 1and –242,516 ~~Quoted~~shares ~~prices~~of incommon ~~active~~stock ~~markets~~were ~~for~~issued ~~identical~~and ~~assets~~outstanding oras ~~liabilities~~of December 31, 2019 and 2018.

~~Level~~NOTE 27 – ~~Observable~~RELATED inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.TRANSACTIONS

~~Level~~Due 3to –related ~~Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.~~parties

InOn ~~accordance~~October ~~with~~1, 2019, the ~~fair~~Company ~~value~~issued ~~accounting~~a ~~requirements,~~convertible ~~companies~~note ~~may~~to ~~choose~~an toun-affiliated ~~measure~~party ~~eligible~~of ~~financial~~$137,312 ~~instruments~~to ~~and~~replace ~~certain~~the ~~other~~full ~~items~~amount atof ~~fair~~related ~~value.~~party ~~The~~advances ~~Company~~that ~~has~~had ~~not~~been ~~elected~~provided to the ~~fair~~Company ~~value~~through ~~option~~December ~~for~~31, ~~any~~2019. ~~eligible~~(see ~~financial~~Note ~~instruments.~~5)

AsDuring ofthe year ended December 31, 2018, ~~and 2017~~ the ~~carrying~~Company ~~value~~received ~~of cash and cash equivalent, accounts payable and~~ loans ~~that~~from ~~are~~the ~~required~~Related toParty beDirector ~~measured~~of ~~at fair value~~$45,814 ~~approximated fair value due~~ to ~~the~~pay ~~short-term~~for ~~nature~~operating expenses and ~~maturity~~repaid ~~of these instruments~~$3,159.

~~Beneficial~~As ~~Conversion~~of ~~Feature~~December 31, 2019 and December 31, 2018, related party loan payable outstanding is $0 and $100,172, respectively.

~~For~~19 ~~conventional~~Table ~~convertible debt where the rate~~ of ~~conversion is below market value, the Corporation records a Beneficial Conversion Feature (the “BCF”) and related debt discount.~~Contents

F-NOTE 8 ~~Table~~– ofINCOME ~~Contents~~TAXES

~~When~~For the ~~Company~~year ~~records~~ended aDecember ~~BCF~~31, 2019, the ~~intrinsic~~Company ~~value~~has ofincurred ~~the~~net ~~BCF~~losses isand, ~~recorded~~therefore, ashas ano ~~debt~~tax ~~discount~~liability. ~~against~~The ~~the~~net ~~face~~deferred ~~amount~~tax ofasset generated by the ~~respective~~loss ~~debt~~carry-forward ~~instrument~~has ~~(offset~~been tofully ~~additional~~reserved. ~~paid~~The cumulative net operating loss carry-inforward ~~capital)~~is $253,150 at December 31, 2019 and ~~amortized~~will expire beginning in the year 2034. NOLs generated in tax years prior to ~~interest~~December ~~expense~~31, ~~over~~2018, ~~the~~can ~~life~~be ofcarryforward ~~the~~for ~~debt~~twenty years, whereas NOLs generated after December 31, 2018 can be carryforward indefinitely.

~~Income~~The ~~Taxes~~provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 21% to the net loss before provision for income taxes for the years ended December 31, 2019 and 2018 are as follows:

The Company recognizes the tax effects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reported for tax purposes.

	Year Ended
	December 31,
	2019			2018
Income tax expense (benefit) at statutory rate	$	(14,033	)	$	(10,998	)
Change in valuation allowance		14,033			10,998
Income tax expense	$	-		$	-

~~Recent~~Net ~~Accounting~~deferred ~~Pronouncements~~tax assets consist of the following components as of December 31, 2019 and 2018:

Management has considered all recent accounting pronouncements issued since the last audit of our financial statements. The Company’s management believes that these recent pronouncements will not have a material effect on the Company’s financial statements.

	December 31,			December 31,
	2019			2018
NOL Carryover	$	53,162		$	39,129
Valuation allowance		(53,162	)		(39,129	)
Net deferred tax asset	$	-		$	-

~~NOTE~~Due 3to –the ~~GOING~~change ~~CONCERN~~in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $253,150 for federal income tax reporting purposes could be subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

The Company’s ~~consolidated~~has ~~financial~~no ~~statements~~uncertain ~~are~~tax ~~prepared~~positions ~~using~~that ~~accounting~~require ~~principles generally accepted in~~ the ~~United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the~~ Company ~~does not have an established source of revenues sufficient~~ to ~~cover~~record ~~its operating costs and to allow it to continue as~~ a ~~going concern~~liability.

~~Under~~The ~~the~~Company ~~going~~had ~~concern~~no ~~assumption,~~accrued anpenalties ~~entity~~and isinterest ~~ordinarily~~related ~~viewed~~to taxes as ~~continuing in business for the foreseeable future with neither the intention nor the necessity~~ of ~~liquidation,~~December ~~ceasing trading~~31, ~~or seeking protection from creditors pursuant to laws or regulations~~2019. ~~Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.~~

~~The~~20 ~~ability~~Table of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the Nature of Business and Trade Name paragraph and eventually attain profitable operations. The accompanying financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern.Contents

~~During~~NOTE ~~the~~9 ~~next~~– ~~year,~~DISCONTINUED the Company’s foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with research and development. The Company may experience a cash shortfall and be required to raise additional capital.OPERATIONS

~~Historically,~~During itthe ~~has~~year ~~mostly~~ended ~~relied~~December ~~upon~~31, ~~internally~~2018, ~~generated funds and funds from~~ the ~~sale~~Company ofdisposed ~~shares~~ of ~~stock~~online tomap ~~finance~~application ~~its operations and growth~~business. ~~Management~~The ~~may~~change ~~raise~~of ~~additional~~the ~~capital~~business ~~through~~qualified ~~future~~as ~~public~~a ordiscontinued ~~private~~operation ~~offerings~~ of the Company’s ~~stock~~and ~~or through loans from private investors~~accordingly, ~~although~~the ~~there~~Company ~~can~~has beexcluded noresults ~~assurance~~of ~~that~~the itoperations ~~will~~from beits ~~able~~Statements toof ~~obtain~~Operations ~~such financing. The Company’s failure~~ to dopresent sothis ~~could~~business ~~have~~in adiscontinued ~~material and adverse effect upon it and its shareholders~~operations.

InThe ~~the~~following ~~past~~table ~~year,~~shows the ~~Company~~results ~~funded~~of operations bywhich ~~using~~are ~~cash~~included ~~proceeds~~in ~~received through~~ the ~~issuance~~loss ~~of common stock and loan~~ from ~~related~~discontinued ~~party. For the coming year, the Company plans to continue to fund the Company through debt and securities sales and issuances until the company generates enough revenues through the~~ operations ~~as stated above.~~:

NOTE 4 – EQUITY

	Year Ended
	December 31,
	2019		2018
Revenue	$	-		6,163
Cost of goods		-		(8,257	)
Gross profit		-		(2,094	)

Operating expenses
General and administration		-		5,906
Professional fees		-		250
Total operating expense				6,156

Loss from discontinued operations		-		(8,250	)
Loss on disposal of assets and liabilities		-		(4,033	)
Loss from discontinued operations, net of tax	$	-	$	(12,283	)

~~The~~NOTE ~~Company~~10 ~~has~~– ~~authorized~~SUBSEQUENT ~~100,000,000 shares of common stock with a par value of $0.0001 and 50,000,000 shares of preferred stock with a par value of $0.0001.~~EVENTS

~~F-9~~Management ~~Table~~has ofevaluated ~~Contents~~potential subsequent events through the date the financial statements were issued. Based on our evaluation no events have occurred that require disclosure.

~~Preferred~~21 ~~stock~~Table of Contents

AsITEM of9. ~~December~~CHANGES ~~31,~~IN ~~2018~~AND ~~and~~DISAGREEMENTS ~~2017,~~WITH ~~there~~ACCOUNTANTS ~~was~~ON noACCOUNTING ~~shares~~AND ~~issued~~FINANCIAL ~~and outstanding.~~DISCLOSURE

~~Common~~There ~~stock~~were no disagreements related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and interim periods.

OnITEM ~~July 10, 2017, the Company issued 5,000 shares to acquire all of the shares of Bio Health Products Inc~~9A. ~~(Note~~CONTROLS ~~1).~~AND PROCEDURES

~~242,516~~Evaluation ~~shares~~Of ofDisclosure ~~common~~Controls ~~stock~~And ~~were issued and outstanding as of December 31, 2018 and 2017.~~Procedures

~~NOTE~~Under 5the –supervision ~~NOTE~~and ~~PAYABLE~~with the participation of our management, including our principal executive officer and principal financial officer (our chief executive officer), we have conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were effective such that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to our company, particularly during the period when this report was being prepared.

OnManagement's ~~June~~Annual 9,Report ~~2017,~~On ~~the~~Internal ~~Company~~Control ~~issued~~Over ~~note~~Financial payable of $7,500 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand. During the year ended December 31, 2018 and 2017, the Company recognized interest expense of $4,693 and $1,693, respectively.Reporting

OnOur ~~August~~management ~~14,~~is ~~2017,~~responsible ~~the~~for ~~Company~~establishing ~~issued~~and ~~note~~maintaining ~~payable~~adequate ofinternal ~~$20,000~~control toover afinancial ~~third~~reporting, ~~party.~~as ~~The~~such ~~note~~term is adefined 40in %Rules ~~interest~~13a-15(f) ~~bearing~~and ~~promissory~~15d-15(f) ~~note~~under ~~that is payable on demand. During~~ the ~~year~~Exchange ~~ended December 31~~Act, ~~2018~~for ~~and~~our ~~2017, the Company recognized interest expense of $11,065 and $3,065, respectively~~company.

OnInternal ~~March~~control 31over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, ~~2018~~in reasonable detail, ~~the~~accurately ~~Company~~and ~~issued~~fairly ~~note~~reflect ~~payable~~the transactions and dispositions of ~~$3,957~~our assets; (2) provide reasonable assurance that transactions are recorded as necessary to apermit ~~third~~preparation ~~party.~~of ~~The~~financial ~~note~~statements isin aaccordance ~~57%~~with ~~interest~~generally ~~bearing~~accepted ~~promissory~~accounting ~~note~~principles, and that isour ~~payable~~receipts onand ~~March~~expenditures ~~31,~~are ~~2023.~~being ~~During~~made ~~the~~only ~~year~~in ~~ended~~accordance ~~December~~with ~~31,~~authorizations ~~2018,~~of ~~the~~its ~~Company~~management ~~recognized~~and ~~interest~~directors; ~~expense~~and (3) provide reasonable assurance regarding prevention or timely detection of $1unauthorized acquisition,~~699~~ use or disposition of our assets that could have a material effect on the financial statements.

AsManagement ofrecognizes ~~December~~that ~~31,~~there ~~2018~~are ~~and~~inherent ~~2017,~~limitations in the ~~Company~~effectiveness ~~owed~~of ~~notes~~any ~~payable~~system of ~~$27~~internal control,~~500~~ and ~~$27~~accordingly,~~500~~ ~~and~~even ~~long-term~~effective ~~notes~~internal ~~payable~~control ofcan ~~$3,957~~provide only reasonable assurance with respect to financial statement preparation and $0may not prevent or detect material misstatements. In addition, ~~respectively~~effective internal control at a point in time may become ineffective in future periods because of changes in conditions or due to deterioration in the degree of compliance with our established policies and procedures.

~~NOTE~~A 6material –weakness ~~CONVERTIBLE~~is ~~NOTE~~a ~~PAYABLE~~significant deficiency, or combination of significant deficiencies, that results in there being a more than remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

OnUnder ~~December~~the ~~31,~~supervision ~~2017,~~and with the ~~Company~~participation ~~issued~~of aour ~~convertible~~chief ~~note~~executive ~~of $4~~officer,~~875~~ ~~with~~management aconducted ~~conversion~~an ~~price~~evaluation of ~~$0.01.~~the ~~The~~effectiveness ~~convertible~~of ~~note~~our isinternal ~~unsecured,~~control ~~bears~~over ~~interest~~financial ~~at 57% per annum~~reporting, ~~has~~as noof ~~maturity~~December ~~date~~31, ~~and~~2019, ~~due~~based on ~~demand.~~the ~~The~~framework ~~Company~~set ~~recorded~~forth ain ~~discount~~Internal onControl-Integrated ~~the~~Framework ~~convertible~~issued ~~note~~by ~~due~~the toCommittee aof ~~beneficial~~Sponsoring ~~conversion~~Organizations ~~feature~~ of ~~$4,875 and amortized $4,875 for~~ the ~~year~~Treadway ~~ended~~Commission ~~December 31, 2017~~(COSO). AsBased ofon ~~December~~our ~~31,~~evaluation ~~2018~~under ~~and~~this ~~2017~~framework, ~~the~~management ~~Company~~concluded ~~had~~that aour ~~convertible~~internal ~~note~~control ofover ~~$4,875.~~financial ~~During~~reporting ~~the~~was ~~year~~not ~~ended~~effective ~~December~~as ~~31,~~of ~~2018 and 2017,~~ the ~~Company~~evaluation ~~recognized~~date ~~interest~~due ~~expense~~to ofthe ~~$2,787~~factors ~~and~~stated ~~$8, respectively~~below.

OnManagement ~~December~~assessed ~~31, 2017,~~ the ~~Company~~effectiveness ~~issued a convertible note~~ of ~~$6,803~~the ~~with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The~~ Company's ~~recorded~~internal acontrol ~~discount~~over onfinancial ~~the~~reporting ~~convertible~~as ~~note due to a beneficial conversion feature~~ of ~~$6,803~~evaluation ~~and~~date ~~amortized $6,803 for the year ended December 31, 2017. As of December 31, 2018~~ and ~~2017,~~identified the ~~Company~~following ~~had~~material ~~a convertible note of $6,803. During the year ended December 31, 2018 and 2017, the Company recognized interest expense of $3,888 and $11, respectively.~~weaknesses:

OnInsufficient ~~December~~Resources: ~~31,~~We ~~2017,~~have ~~the~~an ~~Company~~inadequate ~~issued~~number ~~a convertible note~~ of ~~$11,200~~personnel with arequisite ~~conversion~~expertise ~~price~~in ~~of $0.005. The convertible note is unsecured, bears interest at 50% per annum, has no maturity date and due on demand. The Company recorded a discount on~~ the ~~convertible~~key ~~note~~functional ~~due~~areas ~~to a beneficial conversion feature~~ of ~~$11,200~~finance and ~~amortized $11,200 for the year ended December 31, 2017~~accounting. As of December 31, 2018 and 2017, the Company had a convertible note of $11,200. During the year ended December 31, 2018 and 2017, the Company recognized interest expense of $5,615 and $15, respectively.

~~As of December 31, 2018 and 2017, the Company owed convertible notes payable of $~~22~~,878~~ ~~and~~Table ~~$22,878 and accrued interest~~ of ~~$12,290 and $34, respectively.~~Contents

~~F-10~~Inadequate ~~Table~~Segregation Of Duties: We have an inadequate number of ~~Contents~~personnel to properly implement control procedures.

~~NOTE~~Lack 7Of –Audit ~~RELATED~~Committee ~~TRANSACTIONS~~& Outside Directors On The Company's Board Of Directors: We do not have a functioning audit committee or outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

~~Due~~Management is committed to ~~related~~improving ~~parties~~its internal controls and will (1) continue to use third party specialists to address shortfalls in staffing and to assist the Company with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing outside directors and audit committee members in the future.

~~During~~Management, ~~the~~including ~~year~~our ~~ended~~chief ~~December~~executive 31officer, ~~2018,~~has ~~related~~discussed ~~party~~the ~~loans~~material weakness noted above with our independent registered public accounting firm. Due to the nature of ~~$17~~this material weakness,~~762~~ ~~were~~there ~~forgiven~~is bya ~~the~~more ~~Company’s~~than ~~shareholder~~remote ~~and~~likelihood ~~recorded~~that misstatements which could be material to ~~additional~~the ~~paid~~annual inor ~~capital~~interim financial statements could occur that would not be prevented or detected.

~~During~~This ~~the~~annual ~~year~~report ~~ended~~does ~~December~~not ~~31,~~include ~~2017,~~an ~~the~~attestation ~~Company~~report ~~received~~of ~~loans~~our ~~from~~registered ~~the~~public ~~previous~~accounting ~~Related~~firm ~~Party~~regarding ~~Directors~~internal ofcontrol ~~$6,300~~over tofinancial ~~pay for operating expenses~~reporting. ~~Prior~~Management's toreport ~~the~~was ~~sale~~not ofsubject ~~their~~to ~~shares,~~attestation ~~the~~by ~~loans to~~ the ~~two~~our ~~previous~~registered ~~Related~~public ~~Party~~accounting ~~Directors~~firm ~~were~~pursuant ~~$21,107.~~to ~~Upon~~temporary ~~completion~~rules of the ~~share~~SEC ~~purchase~~that ~~agreements~~permit ~~between~~us ~~the~~to ~~two~~provide ~~previous~~only ~~Related~~management's ~~Party~~report ~~Directors~~in ~~and~~this ~~the~~annual ~~new CEO, the $14,807 was forgiven, and recorded to additional paid-in capital~~report.

~~During~~Changes ~~the~~In ~~year~~Internal ~~ended~~Controls ~~December~~Over ~~31,~~Financial ~~2018 and 2017, the current CEO loaned the Company $45,814 and $49,825 for operational expenses and acquisition of subsidiary and the Company repaid $3,159, and $0, respectively.~~Reporting

~~During~~There ~~the~~have ~~year~~been ~~ended~~no ~~December~~changes ~~31,~~in ~~2017,~~our ~~the~~internal ~~former~~control ~~officer~~over offinancial reporting that occurred during the ~~subsidiary~~last ~~advanced~~fiscal ~~$1,083~~quarter for ~~operational~~our ~~expenses~~fiscal ~~and~~year ~~repaid~~ended $8December 31,~~010~~ 2019 that have materially affected, ~~respectively~~or are reasonably likely to.

AsITEM of9B. ~~December~~OTHER ~~31, 2018 and 2017, related party loan payable outstanding is $100,172 and $75,279, respectively.~~INFORMATION

~~NOTE~~Except as provided above, there is no information to be disclosed in a report on Form 8-K –during ~~INCOME~~the ~~TAXES~~fourth quarter of the year covered by this Form 10-K that has not been previously filed with the Securities and Exchange Commission.

~~For~~23 ~~the~~Table ~~year~~of ended December 31, 2018, the Company has incurred net losses and, therefore, has no tax liability. The net deferred tax asset generated by the loss carry-forward has been fully reserved. The cumulative net operating loss carry-forward is $186,328 at December 31, 2018 and will expire beginning in the year 2032.Contents

~~The~~PART provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 21% to the net loss before provision for income taxes for the years ended December 31, 2018 and 2017 are as follows:III

	For the Year Ended
	December 31,
	2018			2017
Income tax expense (benefit) at statutory rate	$	(10,998	)	$	(13,288	)
Change in valuation allowance		10,998			13,288
Income tax expense	$	-		$	-

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

~~Net~~All ~~deferred~~directors ~~tax~~of ~~assets~~our ~~consist~~company hold office until the next annual meeting of the ~~following~~security ~~components~~holders asor until their successors have been elected and qualified. The officers of ~~December~~our 31company are appointed by our board of directors and hold office until their death, ~~2018~~resignation or removal from office. Our directors and ~~2017~~executive officers, their ages, positions held, and duration as such, are as follows:

	December 31,				December 31,
Name	Position Held with the Company		Age				Date First Elected or Appointed
	2018				2017
Liang Chen	Chief Executive Officer, Chief Financial Officer and director			31			May 12, 2017
NOL Carryover	$	39,129			$	28,131
Valuation allowance		(39,129	)			(28,131	)
Net deferred tax asset	$	-			$	-

~~Due~~Business to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carry forwards of $133,956 for federal income tax reporting purposes could be subject to annual limitations. Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.Experience

The ~~Company~~following ~~has~~is noa ~~uncertain~~brief ~~tax~~account ~~positions~~of the education and business experience during at least the past five years of each director, executive officer and key employee of our company, indicating the person’s principal occupation during that ~~require~~period, and the ~~Company~~name toand ~~record~~principal abusiness ~~liability~~of the organization in which such occupation and employment were carried out.

~~The~~Liang ~~Company~~Chen ~~had~~- noChief ~~accrued~~Executive ~~penalties~~Officer, ~~and~~Chief ~~interest~~Financial ~~related~~Officer toand ~~taxes as of December 31, 2018~~director.

~~NOTE~~Liang 9Chen graduated from the University of Science and Technology of China in 2010. He was employed from June 2010 – ~~DISCONTINUED~~May ~~OPERATIONS~~2015 as a marketing manager at Anhui Technology Import and Export Co where he was tasked with implementing new marketing campaigns for their products. From June 2015 to February 2017 he was the Marketing Director of Anhui Sinonet Science & Technology Co Ltd and has been instrumental in their expansion into the online and emerging markets in countries globally.

~~During~~Our ~~the~~company ~~year~~believes ~~ended~~that ~~December~~Mr. ~~31,~~Chen’s ~~2018,~~professional ~~the~~background ~~Company~~experience ~~disposed~~gives ofhim ~~online~~the ~~map~~qualifications ~~application~~and ~~business.~~skills ~~The~~necessary ~~change~~to ofserve ~~the business qualified~~ as a ~~discontinued~~director ~~operation of the Company~~ and ~~accordingly,~~officer ~~the Company has excluded results~~ of ~~the~~our ~~operations from its Consolidated Statements of Operations to present this business in discontinued operations~~company.

AsTerm ~~a result~~ of ~~disposal of our business, the Company recorded loss on disposal of assets and liabilities of $4,033.~~Office

FOur directors are appointed for a one-11year ~~Table~~term to hold office until the next annual general meeting of ~~Contents~~our stockholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

~~The~~All ~~following~~officers ~~table~~and ~~shows~~directors listed above will remain in office until the ~~results~~next annual meeting of ~~operations~~our ~~which~~stockholders, and until their successors have been duly elected and qualified. There are ~~included~~no agreements with respect to the election of Directors. We have not compensated our Directors for service on our Board of Directors, any committee thereof, or reimbursed for expenses incurred for attendance at meetings of our Board of Directors and/or any committee of our Board of Directors. Officers are appointed annually by our Board of Directors and each Executive Officer serves at the discretion of our Board of Directors. We do not have any standing committees. Our Board of Directors may in the ~~gain~~future ~~from~~determine ~~discontinued~~to ~~operations:~~pay Directors’ fees and reimburse Directors for expenses related to their activities.

	Year Ended
	December 31,
	2018			2017
Revenue	$	6,163			7,761
Cost of goods		(8,257	)		(5,907	)
Gross profit		(2,094	)		1,854
General and administration		5,906			2,696
Professional		250			11,200
Impairment loss		-			87,896
Operating loss		(8,250	)		(99,938	)
Debt forgiveness		-			1,554
Income tax provision		-			-
Loss from discontinued operations, net of tax		(8,250	)		(98,384	)

Table of Contents

~~The~~Employment ~~following table summarizes the carrying amounts of the assets and liabilities from discontinued operations as of December 31, 2018 and 2017, respectively.~~Agreements

	December 31		December 31,
	2018		2017
Cash and cash equivalents	$	-	$	1,488
Inventory		-		3,201
Total Assets from discontinued operations	$	-	$	4,689
Accounts payable and accrued liabilities	$	-	$	1,014
Total Liabilities from discontinued operations	$	-	$	1,014

We have no formal employment agreements with any of our directors or officers.

~~NOTE~~Family ~~10 – SUBSEQUENT EVENT~~Relationships

~~The~~There ~~Company~~are ~~evaluated~~no ~~all~~family ~~events~~relationships orbetween ~~transactions~~any ~~that~~of ~~occurred~~our ~~after December 31~~directors, ~~2018,~~executive ~~through~~officers ~~the~~and ~~date~~proposed ofdirectors ~~this filing. The Company determined that it does not have any subsequent event requiring recording~~ or ~~disclosure~~executive ~~in the financial statements for the year ended December 31, 2018~~officers.

~~F-12~~Involvement ~~Table~~in ofcertain ~~Contents~~legal proceedings.

~~Item~~To 9.the ~~Changes~~best inof ~~and~~our ~~Disagreements~~knowledge, ~~With~~none ~~Accountants~~of onour ~~Accounting~~directors ~~and~~or ~~Financial~~executive ~~Disclosure~~officers has, during the past ten years:

~~There~~1. ~~were~~been noconvicted ~~disagreements~~in ~~related~~a criminal proceeding or been subject to ~~accounting~~a ~~principles~~pending criminal proceeding (excluding traffic violations and other minor offences); 2. had any bankruptcy petition filed by or ~~practices,~~against ~~financial~~the ~~statement~~business ~~disclosure~~or property of the person, ~~internal~~or ~~controls~~of any partnership, corporation or ~~auditing~~business ~~scope~~association of which he was a general partner or ~~procedure~~executive ~~during~~officer, either at the ~~two~~time ~~fiscal~~of the bankruptcy filing or within two years prior to that time; 3. been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and ~~interim~~loan, ~~periods~~or insurance activities, or to be associated with persons engaged in any such activity; 4. been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

~~Item~~25 ~~9A.~~Table ~~Controls~~of ~~and Procedures~~Contents

Evaluation Of Disclosure Controls And Procedures

5.	been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

6.	been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26)), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29)), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

~~Under~~Section ~~the supervision and with the participation of our management, including our principal executive officer and principal financial officer~~ 16(~~our chief executive officer~~a), weBeneficial ~~have~~Ownership ~~conducted~~Reporting an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as of the end of the period covered by this report. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were effective such that the material information required to be included in our Securities and Exchange Commission reports is accumulated and communicated to our management, including our principal executive and financial officer, recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms relating to our company, particularly during the period when this report was being prepared.Compliance

~~Management's~~Section ~~Annual~~16(a) ~~Report~~of Onthe ~~Internal~~Securities ~~Control~~Exchange ~~Over~~Act ~~Financial~~of ~~Reporting~~1934, as amended, requires our executive officers and directors and persons who own more than 10% of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our shares of common stock and other equity securities, on Forms 3, 4 and 5, respectively. Executive officers, directors and greater than 10% shareholders are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file.

~~Our~~Based ~~management~~solely ison ~~responsible~~our ~~for~~review ~~establishing~~of ~~and~~the ~~maintaining~~copies ~~adequate~~of ~~internal~~such ~~control~~forms ~~over~~received ~~financial~~by our company, or written representations from certain reporting persons that no Form 5s were required for those persons, aswe ~~such~~believe ~~term~~that, isduring ~~defined~~the infiscal ~~Rules~~year ~~13a-15(f)~~ended December 31, 2019, all filing requirements applicable to our officers, directors and ~~15d-15(f)~~greater ~~under~~than ~~the~~10% ~~Exchange~~beneficial ~~Act~~owners as well as our officers, ~~for~~directors and greater than 10% beneficial owners of our ~~company.~~subsidiaries were complied with, with the exception of the following:

Internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of its management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Name

Number of

Late Reports

Number of

Transactions Not

Reported on a

Timely Basis

Failure to File

Requested Forms

Liang Chen

~~Management~~(1) ~~recognizes~~The ~~that~~insider ~~there~~has ~~are~~yet ~~inherent limitations in the effectiveness of any system of internal control, and accordingly, even effective internal control can provide only reasonable assurance with respect~~ to ~~financial~~file ~~statement~~a ~~preparation~~Form ~~and may not prevent or detect material misstatements. In addition~~3, ~~effective~~Initial ~~internal~~Statement ~~control at a point in time may become ineffective in future periods because~~ of ~~changes~~Beneficial ~~in conditions or due to deterioration in the degree of compliance with our established policies and procedures~~Ownership.

ACode ~~material weakness is a significant deficiency, or combination~~ of ~~significant deficiencies, that results in there being a more than remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.~~Ethics

~~Under~~We ~~the~~have ~~supervision~~not ~~and~~adopted ~~with~~a ~~the~~Code ~~participation~~ of ~~our~~Business ~~chief~~Conduct ~~executive~~and officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting, as of December 31, 2018, based on the framework set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)Ethics. ~~Based on our evaluation under this framework, management concluded that our internal control over financial reporting was not effective as of the evaluation date due to the factors stated below.~~

~~Management~~Board ~~assessed the effectiveness of the Company's internal control over financial reporting as of evaluation date~~ and ~~identified~~Committee ~~the following material weaknesses:~~Meetings

~~Insufficient~~Our ~~Resources:~~board Weof ~~have~~directors anheld ~~inadequate~~no ~~number~~formal meetings during the year ended December 31, 2019. All proceedings of ~~personnel~~the board of directors were conducted by resolutions consented to in writing by all the directors and filed with ~~requisite~~the ~~expertise~~minutes of the proceedings of the directors. Such resolutions consented to in writing by the ~~key~~directors ~~functional~~entitled ~~areas~~to vote on that resolution at a meeting of ~~finance~~the directors are, according to the Colorado Revised Statutes and ~~accounting~~our Bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

13Nomination ~~Table of Contents~~Process

~~Inadequate~~As ~~Segregation~~of OfDecember ~~Duties:~~31, We2019, we did not effect any material changes to the procedures by which our shareholders may recommend nominees to our board of directors. Our board of directors does not have ana ~~inadequate~~policy ~~number~~with regards to the consideration of ~~personnel~~any director candidates recommended by our shareholders. Our board of directors has determined that it is in the best position to ~~properly~~evaluate ~~implement~~our ~~control~~company’s ~~procedures~~requirements as well as the qualifications of each candidate when the board considers a nominee for a position on our board of directors. If shareholders wish to recommend candidates directly to our board, they may do so by sending communications to the president of our company at the address on the cover of this annual report.

~~Lack~~26 OfTable ~~Audit Committee & Outside Directors On The Company's Board Of Directors: We do not have a functioning audit committee or outside directors on our board~~ of ~~directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.~~Contents

~~Management~~Audit is committed to improving its internal controls and will (1) continue to use third party specialists to address shortfalls in staffing and to assist the Company with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing outside directors and audit committee members in the future.Committee

~~Management,~~Currently ~~including~~ our ~~chief~~audit ~~executive~~committee ~~officer,~~consists ~~has~~of ~~discussed~~our ~~the~~entire ~~material~~board ~~weakness~~of ~~noted~~directors. ~~above~~We ~~with~~do ~~our~~not ~~independent~~have ~~registered~~a ~~public~~standing ~~accounting~~audit ~~firm.~~committee ~~Due~~as towe ~~the~~currently ~~nature~~have oflimited ~~this~~working ~~material~~capital ~~weakness,~~and ~~there~~minimal isrevenues. aShould ~~more~~we ~~than~~be ~~remote~~able ~~likelihood~~to ~~that~~raise ~~misstatements~~sufficient ~~which~~funding ~~could~~to beexecute ~~material~~our tobusiness ~~the~~plan, ~~annual~~we orwill ~~interim~~form ~~financial~~an ~~statements~~audit, ~~could~~compensation ~~occur~~committee ~~that~~and ~~would~~other ~~not~~applicable becommittees ~~prevented~~utilizing orour ~~detected~~directors’ expertise.

~~This~~Audit ~~annual~~Committee ~~report~~Financial does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management's report in this annual report.Expert

~~Changes~~Currently Inour ~~Internal~~audit ~~Controls~~committee ~~Over~~consists ~~Financial~~of ~~Reporting~~our entire board of directors. We do not currently have a director who is qualified to act as the head of the audit committee.

~~There~~ITEM ~~have~~11. ~~been~~EXECUTIVE no changes in our internal control over financial reporting that occurred during the last fiscal quarter for our fiscal year ended December 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.COMPENSATION

~~Item~~The ~~9B.~~particulars ~~Other~~of ~~Information~~the compensation paid to the following persons:

~~None.~~(a) our principal executive officer; (b) each of our two most highly compensated executive officers who were serving as executive officers at the end of the years ended December 31, 2019 and 2018; and (c) up to two additional individuals for whom disclosure would have been provided under (b) but for the fact that the individual was not serving as our executive officer at the end of the years ended December 31, 2019 and 2018, who we will collectively refer to as the named executive officers of our company, are set out in the following summary compensation table, except that no disclosure is provided for any named executive officer, other than our principal executive officers, whose total compensation did not exceed $100,000 for the respective fiscal year:

14 Table of Contents

SUMMARY COMPENSATION TABLE

Name and Principal Position

Year

Salary

($)

Bonus

($)

Stock

Awards

($)

Option

Awards

($)

Non-Equity

Incentive Plan

Compensa-tion

($)

Change in Pension

Value and

Nonqualified Deferred

Compensa-tion

Earnings

($)

All

Other

Compensa-tion

($)

Total

($)

Liang Chen⁽¹⁾CEO, CFO, and Director

2019

2018

421,912

~~PART~~(1) ~~III~~Mr. Chen was appointed CEO, CFO and Director on May 12, 2017.

~~Item~~There ~~10.~~are ~~Directors~~no arrangements or plans in which we provide pension, ~~Executive~~retirement ~~Officers~~or similar benefits for directors or executive officers. Our directors and ~~Corporate~~executive ~~Governance~~officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

~~All~~27 ~~directors~~Table of our company hold office until the next annual meeting of the security holders or until their successors have been elected and qualified. The officers of our company are appointed by our board of directors and hold office until their death, resignation or removal from office. Our directors and executive officers, their ages, positions held, and duration as such, are as follows:Contents

Name		Position Held with the Company		Age		Date First Elected or Appointed
Liang Chen		Chief Executive Officer, Chief Financial Officer and director		30		May 12, 2017

Grants of Plan-Based Awards

~~Business~~During ~~Experience~~the fiscal year ended December 31, 2019 we did not grant any stock options.

~~The~~Option ~~following~~Exercises ~~is a brief account of the education~~ and ~~business~~Stock ~~experience~~Vested during at least the past five years of each director, executive officer and key employee of our company, indicating the person’s principal occupation during that period, and the name and principal business of the organization in which such occupation and employment were carried out.

~~Liang~~During ~~Chen~~our -fiscal ~~Chief~~year ~~Executive~~ended ~~Officer~~December 31, ~~Chief~~2019 ~~Financial~~there ~~Officer~~were ~~and~~no ~~director~~options exercised by our named officers.

~~Liang~~Compensation ~~Chen graduated from the University~~ of Science and Technology of China in 2010. He was employed from June 2010 – May 2015 as a marketing manager at Anhui Technology Import and Export Co where he was tasked with implementing new marketing campaigns for their products. From June 2015 to February 2017 he was the Marketing Director of Anhui Sinonet Science & Technology Co Ltd and has been instrumental in their expansion into the online and emerging markets in countries globally.Directors

~~Our~~On ~~company~~March ~~believes~~21, ~~that~~2019, ~~Mr.~~our ~~Chen’s~~majority ~~professional~~shareholder ~~background~~and ~~experience~~our ~~gives~~sole ~~him~~director, approved the ~~qualifications~~issuance ~~and~~of ~~skills~~7,000,000 ~~necessary~~shares of common stock valued at $421,912 to ~~serve~~Liang Chen, our Chief Executive Officer as acompensation ~~director~~for ~~and~~management ~~officer~~services ofprovided to our company.

~~Term~~Pension, ofRetirement ~~Office~~or Similar Benefit Plans

~~Our~~There ~~directors~~ are ~~appointed~~no ~~for~~arrangements aor ~~one-year~~plans ~~term~~in towhich ~~hold~~we ~~office~~provide ~~until~~pension, ~~the~~retirement ~~next~~or ~~annual~~similar ~~general~~benefits ~~meeting~~for ofdirectors ~~our~~or ~~stockholders~~executive officers. We have no material bonus or ~~until~~profit ~~removed~~sharing ~~from~~plans ~~office~~pursuant into ~~accordance~~which ~~with~~cash ~~our~~or ~~bylaws.~~non-cash ~~Our~~compensation ~~officers~~is ~~are~~or ~~appointed~~may bybe ~~our~~paid ~~board~~to ofour directors ~~and~~or ~~hold~~executive ~~office~~officers, ~~until~~except ~~removed~~that bystock options may be granted at the discretion of the board of directors or a committee thereof.

~~All~~Indebtedness ~~officers and directors listed above will remain in office until the next annual meeting~~ of ~~our stockholders, and until their successors have been duly elected and qualified. There are no agreements with respect to the election of~~ Directors~~. We have not compensated our Directors for service on our Board of Directors~~, ~~any~~Senior ~~committee thereof~~Officers, orExecutive ~~reimbursed for expenses incurred for attendance at meetings of our Board of Directors and/or any committee of our Board of Directors.~~ Officers ~~are appointed annually by our Board of Directors~~ and ~~each~~Other Executive Officer serves at the discretion of our Board of Directors. We do not have any standing committees. Our Board of Directors may in the future determine to pay Directors’ fees and reimburse Directors for expenses related to their activities.Management

15None ~~Table~~of our directors or executive officers or any associate or affiliate of ~~Contents~~our company during the last two fiscal years, is or has been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

~~Employment~~ITEM ~~Agreements~~12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

WeThe ~~have~~following notable ~~formal~~sets ~~employment~~forth ~~agreements~~certain ~~with~~information concerning the number of shares of our common stock owned beneficially as of March 12, 2020 by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our ~~directors~~voting securities, (ii) members of our Board of Directors, and or (iii) our executive officers. Unless otherwise indicated, the stockholder listed possesses sole voting and investment power with respect to the shares shown.

Family Relationships

Name and Address of Beneficial Owner

Amount and Nature ofBeneficial Ownership

Percentageof Class⁽¹⁾

Liang Chen

Xiang yan lu xi 255

Hao 3-1-402 shi,

Wo yang xian cheng guang zhen

An hui sheng, PRC 233600

7,205,000 common stock / indirect ⁽²⁾

89.6%

Directors and Executive Officers as a Group

7,205,000 common stock

89.6%

~~There are no family relationships between any of our directors, executive officers and proposed directors or executive officers.~~ ________________

Involvement in Certain Legal Proceedings

	(1)	Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on March 12, 2020. As of March 12, 2020 there were 8,042,516 shares of our company’s common stock issued and outstanding.

	(2)	200,000 shares are owned by Peak Global Holdings Limited. Mr. Chen is the sole shareholder of Peak Global Holdings Limited. 7,00,500 shares are owned by Mr. Chen.

To28 ~~the~~Table ~~best~~ of ~~our knowledge, none of our directors or executive officers has, during the past ten years:~~Contents

16No ~~Table~~director, executive officer, shareholder holding at least 5% of ~~Contents~~shares of our common stock, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since the year ended December 31, 2019, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last three completed fiscal years.

~~Compliance~~ITEM ~~with~~14. ~~Section~~PRINCIPAL ~~16(A)~~ACCOUNTING ofFEES ~~the~~AND ~~Securities Exchange Act of 1934~~SERVICES

~~Section~~The ~~16(a)~~aggregate offees ~~the~~billed ~~Securities~~for ~~Exchange~~the ~~Act~~most ofrecently ~~1934,~~completed asfiscal ~~amended,~~year ~~requires~~ended ~~our~~December ~~executive~~31, ~~officers~~2019and ~~and~~for ~~directors~~fiscal ~~and~~year ~~persons~~ended ~~who~~December ~~own~~31, ~~more~~2018 ~~than~~for ~~10%~~professional ofservices arendered ~~registered~~by ~~class~~the ofprincipal ~~our~~accountant ~~equity~~for ~~securities to file with~~ the ~~SEC~~audit ~~initial statements~~ of ~~beneficial~~our ~~ownership,~~annual ~~reports~~financial ofstatements ~~changes in ownership~~ and ~~annual~~review ~~reports concerning their ownership~~ of ~~our~~the ~~shares~~financial ofstatements ~~common~~included ~~stock~~in ~~and~~our ~~other~~quarterly ~~equity~~reports ~~securities,~~ on ~~Forms~~Form 3,10-Q 4 and 5,services ~~respectively.~~that ~~Executive~~are ~~officers,~~normally ~~directors~~provided ~~and~~by ~~greater~~the ~~than~~accountant ~~10%~~in ~~shareholders~~connection ~~are~~with ~~required~~statutory byand ~~the~~regulatory ~~SEC~~filings ~~regulations~~or toengagements ~~furnish~~for usthese ~~with~~fiscal ~~copies~~periods ofwere ~~all~~as ~~Section 16(a) reports they file.~~follows:

Based solely on our review of the copies of such forms received by our company, or written representations from certain reporting persons that no Form 5s were required for those persons, we believe that, during the fiscal year ended December 31, 2018, all filing requirements applicable to our officers, directors and greater than 10% beneficial owners as well as our officers, directors and greater than 10% beneficial owners of our subsidiaries were complied with, with the exception of the following:

Fee Category	Year Ended December 31, 2019		Year Ended December 31, 2018

Audit Fees	$	23,900	$	15,800
Audit-Related Fees		-		-
Tax Fees		-		-
All Other Fees		-		-
Total Fees	$	23,900	$	15,800

Name		Number of Late Reports		Number of Transactions Not Reported on a Timely Basis		Failure to File Requested Forms
Liang Chen		1		0		1

Audit committee policies & procedures

~~(1)~~We ~~The~~do ~~insider~~not ~~has~~currently ~~yet~~have toa ~~file~~standing aaudit ~~Form~~committee. 3,The ~~Initial~~above ~~Statement~~services ofwere ~~Beneficial~~approved ~~Ownership~~by our Board of Directors.

~~Code~~29 Table of ~~Ethics~~Contents

WePART ~~have not adopted a Code of Business Conduct and Ethics.~~IV

~~Board~~ITEM ~~and~~15. ~~Committee~~EXHIBITS, ~~Meetings~~FINANCIAL STATEMENT SCHEDULES

Our board of directors held no formal meetings during the year ended December 31, 2018. All proceedings of the board of directors were conducted by resolutions consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at (a) ~~meeting~~Financial ~~of the directors are, according to the Nevada General Corporate Law and our Bylaws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.~~Statements

Nomination Process

	(1)	Financial statements for our company are listed in the index under Item 8 of this document.

	(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

As(b) of December 31, 2018, we did not effect any material changes to the procedures by which our shareholders may recommend nominees to our board of directors. Our board of directors does not have a policy with regards to the consideration of any director candidates recommended by our shareholders. Our board of directors has determined that it is in the best position to evaluate our company’s requirements as well as the qualifications of each candidate when the board considers a nominee for a position on our board of directors. If shareholders wish to recommend candidates directly to our board, they may do so by sending communications to the president of our company at the address on the cover of this annual report.Exhibits

17 Table of Contents

EXHIBIT NUMBER		Exhibit Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Rule 13(a)-14(a)/15(d)-14(a) Certification of Chief Executive Officer and Chief Financial Officer
(32)		Section 1350 Certifications
32.1**		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
(100)		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

~~Audit Committee~~_________

~~Currently~~*Filed ~~our audit committee consists of our entire board of directors~~herewith. We do not have a standing audit committee as we currently have limited working capital and minimal revenues. Should we be able to raise sufficient funding to execute our business plan, we will form an audit, compensation committee and other applicable committees utilizing our directors’ expertise.

~~Audit~~**Furnished ~~Committee Financial Expert~~herewith.

~~Currently~~ITEM ~~our audit committee consists of our entire board of directors~~16. WeFORM do10-K ~~not currently have a director who is qualified to act as the head of the audit committee.~~ SUMMARY

~~Item 11~~None. ~~Executive Compensation~~

~~The~~30 ~~particulars~~Table of ~~the compensation paid to the following persons:~~Contents

(a) our principal executive officer; (b) each of our two most highly compensated executive officers who were serving as executive officers at the end of the years ended December 31, 2018 and 2017; and (c) up to two additional individuals for whom disclosure would have been provided under (b) but for the fact that the individual was not serving as our executive officer at the end of the years ended December 31, 2018 and 2017, who we will collectively refer to as the named executive officers of our company, are set out in the following summary compensation table, except that no disclosure is provided for any named executive officer, other than our principal executive officers, whose total compensation did not exceed $100,000 for the respective fiscal year:SIGNATURES

SUMMARY COMPENSATION TABLE
Name and Principal Position	Year	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensa-tion ($)	Change in Pension Value and Nonqualified Deferred Compensa-tion Earnings ($)	All Other Compensa-tion ($)	Total ($)
Liang Chen(1) CEO, CFO, and Director	2018 2017	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil	Nil Nil
Omri Morchi (2) Former President and Director	2018 2017	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil
Eden Shoua(3) Former Treasurer, Secretary and Director	2018 2017	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil	N/A Nil

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

(1)	Mr. Chen was appointed CEO, CFO and Director on May 12, 2017.
	BIOSCIENCE NEUTRACEUTICALS, INC.
(2)	Mr. Morchi was appointed President and Director on June 15, 2010 and resigned all positions on May 12, 2017.
Dated March 30, 2020	By:	/s/ Liang Chen
(3)	Ms. Shoua was appointed Secretary, Treasurer and Director on June 15, 2010 and resigned all positions on May 12, 2017.
		Liang Chen
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial
		Officer and Principal Accounting Officer)

18Pursuant ~~Table~~to the requirements of ~~Contents~~the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.

Dated March 30, 2020		/s/ Liang Chen
		Liang Chen
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial
		Officer and Principal Accounting Officer)

~~Grants of Plan-Based Awards~~31

During the fiscal year ended December 31, 2018 we did not grant any stock options.

Option Exercises and Stock Vested

During our fiscal year ended December 31, 2018 there were no options exercised by our named officers.

Compensation of Directors

We do not have any agreements for compensating our directors for their services in their capacity as directors, although such directors are expected in the future to receive stock options to purchase shares of our common stock as awarded by our board of directors.

No compensation was paid to non-employee directors for the year ended December 31, 2018.

Pension, Retirement or Similar Benefit Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.

Indebtedness of Directors, Senior Officers, Executive Officers and Other Management

None of our directors or executive officers or any associate or affiliate of our company during the last two fiscal years, is or has been indebted to our company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth, as of April 5, 2019, certain information with respect to the beneficial ownership of our common and preferred shares by each shareholder known by us to be the beneficial owner of more than 5% of our common and preferred shares, as well as by each of our current directors and executive officers as a group. Each person has sole voting and investment power with respect to the shares of common and preferred stock, except as otherwise indicated. Beneficial ownership consists of a direct interest in the shares of common and preferred stock, except as otherwise indicated.

19 Table of Contents

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percentage of Class(1)
Liang Chen Xiang yan lu xi 255 Hao 3-1-402 shi, Wo yang xian cheng guang zhen An hui sheng, PRC 233600	200,000 common stock / indirect (2)	84.2%
Directors and Executive Officers as a Group	200,000 common stock	84.2%

_______________

	(1)	Under Rule 13d-3, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person (and only such person) by reason of these acquisition rights. As a result, the percentage of outstanding shares of any person as shown in this table does not necessarily reflect the person’s actual ownership or voting power with respect to the number of shares of common stock actually outstanding on April 5, 2019. As of April 5, 2019 there were 242,516 shares of our company’s common stock issued and outstanding.
	(2)	These shares are owned by Peak Global Holdings Limited. Mr. Chen is the sole shareholder of Peak Global Holdings Limited.

Changes in Control

We are unaware of any contract or other arrangement or provisions of our Articles or Bylaws the operation of which may at a subsequent date result in a change of control of our company. There are not any provisions in our Articles or Bylaws, the operation of which would delay, defer, or prevent a change in control of our company.

Item 13. Certain Relationships and Related Transactions, and Director Independence

Except as disclosed herein, no director, executive officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since the year ended December 31, 2018, in which the amount involved in the transaction exceeded or exceeds the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last three completed fiscal years.

Director Independence

We currently act with one director, Liang Chen.

We have determined we do not have an independent director, as that term is used in Rule 4200(a)(15) of the Rules of National Association of Securities Dealers.

Currently our audit committee consists of our entire board of directors. We currently do not have nominating, compensation committees or committees performing similar functions. There has not been any defined policy or procedure requirements for shareholders to submit recommendations or nomination for directors.

20 Table of Contents

From inception to present date, we believe that the members of our audit committee and the board of directors have been and are collectively capable of analyzing and evaluating our financial statements and understanding internal controls and procedures for financial reporting.

Item 14. Principal Accounting Fees and Services

The aggregate fees billed for the most recently completed fiscal year ended December 31, 2018 and for fiscal year ended December 31, 2017 for professional services rendered by the principal accountant for the audit of our annual financial statements and review of the financial statements included in our quarterly reports on Form 10-Q and services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for these fiscal periods were as follows:

	Year Ended
	December 31, 2018		December 31, 2017
Audit Fees	$	15,800	$	8,900
Audit Related Fees	Nil		Nil
Tax Fees	Nil		Nil
All Other Fees	Nil		Nil
Total	$	15,800	$	8,900

Our board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and approved by the board of directors either before or after the respective services were rendered.

Our board of directors has considered the nature and amount of fees billed by our independent auditors and believes that the provision of services for activities unrelated to the audit is compatible with maintaining our independent auditors’ independence.

21 Table of Contents

PART IV

Item 15. Exhibits, Financial Statement Schedules

(a) Financial Statements

	(1)	Financial statements for our company are listed in the index under Item 8 of this document.
	(2)	All financial statement schedules are omitted because they are not applicable, not material or the required information is shown in the financial statements or notes thereto.

(b) Exhibits

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1**		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101**		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

___________

* Filed herewith.

** Furnished herewith

22 Table of Contents

SIGNATURES

		BIOSCIENCE NEUTRACEUTICALS, INC.
		(Registrant)
Dated: April 9, 2019		/s/ Liang Chen
		Liang Chen
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Dated: April 9, 2019		/s/ Liang Chen
		Liang Chen
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · BIOSCIENCE NEUTRACEUTICALS, INC.